document incorporate reference portion proxy statement registrant annual meeting stockholder hold file day conclusion registrant fiscal year end december incorporate reference iii annual report bristolmyer squibb company index december item business acquisition divestiture product intellectual property product exclusivity research development alliance marketing distribution customer competition pricing price constraint market access government regulation source availability raw material manufacturing quality assurance environmental regulation employee foreign operation bristolmyer squibb website item risk factor item unresolved staff comment item property item legal proceeding item safety disclosure executive officer registrant item market registrant common stock stockholder matter item select financial datum item management discussion analysis financial condition result operation item quantitative qualitative disclosure market risk item financial statement supplementary datum consolidate statement earning comprehensive income consolidate balance sheet consolidate statement cash flow note financial statement item change disagreement accountant account financial disclosure item control procedure item information iii item director executive officer registrant item executive compensation item security ownership certain beneficial owner management relate stockholder matter item certain relationship relate transaction item auditor fee item exhibit financial statement schedule item summary signature summary abbreviate term exhibit index indicate brand name product trademark own bms specific trademark ownership information include exhibit indexpart item business general bristolmyers squibb company incorporate law state delaware august bristolmyer company successor new york business start bristolmyer company change bristolmyer squibb company result merger engage discovery development licensing manufacturing marketing distribution sale biopharmaceutical product global basis refer summary abbreviate term end term document operate segmentbiopharmaceutical additional information business segment refer item financial statementsnote business segment information compete worldwide researchbase drug company small research company generic drug manufacturer product sell worldwide primarily wholesaler retail pharmacy hospital government entity medical profession manufacture product puerto rico foreign country revenue come product follow therapeutic class oncology cardiovascular immunoscience virology include hiv infection percentage revenue significant regioncountry follow year end december dollar millions united states europe japan total revenue acquisition divestiture acquisition year include cormorant padlock cardioxyl flexus ipierian amylin inhibitex enter license collaboration arrangement divestiture year include certain otc product investigational hiv medicine business erbitux north america certain mature otc product business diabete business transaction continue allow focus resource growth opportunity drive great longterm value product intellectual property product exclusivity pharmaceutical product include chemicallysynthesize drug small molecule product produce biological process call biologic small molecule drug typically administer orally form pill tablet drug delivery mechanism biologic typically administer patient injection intravenous infusion product summary include approve indication information alliance arrangement product refer alliance item financial statementsnote alliance empliciti empliciti biological product humanize monoclonal antibody treatment multiple myeloma opdivo opdivo biological product fully human monoclonal antibody bind nkt cell opdivo receive approval indication include melanoma head neck lung kidney blood cancer opdivoyervoy regimen approve multiple market treatment melanoma ongoing potentially registrational trial opdivo tumor type disease area sprycel sprycel multitargete tyrosine kinase inhibitor approve firstline treatment adult philadelphia chromosomepositive chronic myeloid leukemia chronic phase treatment adult chronic accelerate myeloid lymphoid blast phase chronic myeloid leukemia resistance intolerance prior therapy include gleevec imatinib mesylate yervoy yervoy biological product monoclonal antibody treatment patient unresectable metastatic melanoma eliquis eliquis oral factor inhibitor target stroke prevention atrial fibrillation prevention treatment vte disorder orencia orencia biological product fusion protein novel immunosuppressive activity target initially adult patient moderately severely active inadequate response certain currently available treatment baraclude baraclude potent selective inhibitor hepatitis virus hepatitis franchise daklinza daclatasvir dcv oral small molecule nsa replication complex inhibitor treatment hcv approve use gilead sofosbuvir sunvepra asunaprevir asv oral small molecule protease inhibitor treatment hcv dual regimen dcvasv japan currently registration china beclabuvir bcv oral small molecule nonnucleoside nsb inhibitor treatment hcv triple combination tablet ximency dcvasvbcv japan reyataz franchise reyataz protease inhibitor treatment hiv reyataz franchise include reyataz combination therapy evotaz atazanavir cobicistat oncedaily single tablet drug regiman combine reyataz gilead tybost cobicistat treatment hiv infection adult sustiva franchise sustiva nonnucleoside reverse transcriptase inhibitor treatment hiv sustiva franchise include sustiva antiretroviral drug treatment hiv bulk efavirenz include combination therapy atripla efavirenz emtricitabine tenofovir disoproxil fumarate oncedaily single tablet threedrug regimen combine sustiva gilead truvada emtricitabine tenofovir disoproxil fumarate license number patent foreign country primarily cover product develop brand name trademark product consider overall protection patent trademark license intellectual property right material value act protect right infringement pharmaceutical industry majority innovative product commercial value usually realize period product market exclusivity product market exclusivity generally determine form intellectual property patent right hold innovator company regulatory form exclusivity innovative drug entitle patent key determinant market exclusivity brand pharmaceutical patent provide innovator right exclude practice invention relate medicine patent cover thing active ingredient use drug product pharmaceutical formulation drug delivery mechanism process intermediate useful manufacture product protection individual product extend vary period accordance expiration date patent country protection afford vary country country depend type patent scope coverage availability meaningful legal remedy country market exclusivity influence regulatory intellectual property right develop country provide certain nonpatent incentive development medicine example japan certain country regulatory intellectual property right offer incentive research medicine rare disease orphan drug medicine useful treat pediatric patient incentive extend market exclusivity period product patent term japan provide minimum period time approval new drug regulatory agency rely innovators data approve competitor generic copy datum protection region china questionable datum protection law enforceable certain market patent protection form market exclusivity expire datum protection particular importance regulatory form exclusivity prevent competitor gain regulatory approval prior expiration regulatory data exclusivity basis competitor safety efficacy datum drug drug identical market innovator specific aspect law govern market exclusivity datum protection pharmaceuticals vary country country follow summarize key exclusivity rule market represent significant sale united state key product protect patent vary term depend type patent filing date significant portion product patent life lose time take innovative company develop obtain regulatory approval new drug compensation lose patent term innovator depend number factor extend expiration date patent maximum term year provide extension cause patent effect year date drug approval company seek market innovative pharmaceutical submit complete set safety efficacy datum fda innovative pharmaceutical chemical company file nda medicine biological product bla file type application file affect regulatory exclusivity right chemical product competitor seek launch generic substitute chemical innovative drug file anda fda anda generic manufacturer need demonstrate bioequivalence generic substitute approve nda drug anda rely safety efficacy datum previously file innovator nda innovator company require list certain patent cover medicine fda commonly know orange book absent successful patent challenge fda approve anda innovators list patent expire innovator market product year generic manufacturer file anda allege patent list orange book innovators nda invalid infringe allegation commonly know paragraph certification innovator decide file patent infringement suit generic manufacturer time time anda include paragraph certification file respect certain product evaluate andas casebycase basis warrant file suit generic manufacturer protect patent right addition benefit patent protection certain innovative pharmaceutical product receive period regulatory exclusivity nda designate orphan drug receive seven year exclusivity orphan indication time period nda andas drug product approve orphan use company earn month additional exclusivity drug specific clinical trial conduct write request fda study use medicine treat pediatric patient submission fda prior loss basic exclusivity medicine approve nda receive type regulatory data protection innovative chemical pharmaceutical entitle year regulatory data protection competitor file fda approval generic substitutes innovators patent challenge describe generic manufacturer file anda fourth year fiveyear datum protection period pharmaceutical drug product contain active ingredient previously approve nda approve new formulation drug new indication basis new clinical trial receive year datum protection formulation indication biologic product healthcare legislation enact create approval pathway biosimilar version innovative biological product previously exist prior time innovative biologic essentially unlimited regulatory exclusivity new regulatory mechanism fda approve product similar generic copy innovative biologic basis extensive datum require bla innovator market product year manufacturer file application approval biosimilar version innovator product application approval biosimilar file year approval innovator product qualify innovative biological product receive year regulatory exclusivity mean fda approve biosimilar version year innovative biological product approve fda law provide mechanism innovator enforce patent protect innovative biological product biosimilar applicant challenge patent patent litigation begin early year innovative biological product approve fda increase likelihood generic biosimilar challenge innovators intellectual property increase risk loss innovator market exclusivity generic company increasingly seek challenge innovator basic patent cover major pharmaceutical product second statutory regulatory provision limit ability innovator company prevent generic biosimilar drug approve launch patent litigation ongoing result development possible predict length market exclusivity particular product certainty base solely expiration relevant patent current form regulatory exclusivity european union patent pharmaceutical product generally enforceable extended compensate patent term lose regulatory review process extension grant countrybycountry basis primary route use obtain marketing authorization pharmaceutical product centralized procedure procedure compulsory certain pharmaceutical product particular biotechnological process available certain new chemical compound product company seek market innovative pharmaceutical product centralized procedure file complete set safety datum efficacy datum maa ema ema evaluate maa provide recommendation approve deny maa possible new chemical product obtain marketing authorization mutual recognition procedure application single member state member state approve pharmaceutical product national procedure applicant submit approval mutual recognition procedure member state obtain marketing authorization approval company obtain pricing reimbursement pharmaceutical product typically subject member state law certain country process place simultaneously product market country process complete company market new product pricing reimbursement procedure month year complete product marketing authorization file octobernovember subject regime year innovator receive community authorization medicinal product generic company file marketing authorization application product health authority market authorization application approve generic company commercialize product year elapse initial marketing authorization grant innovator possible extension year available innovator year marketing authorization obtain additional indication significant clinical benefit comparison exist treatment product file prior octobernovember year period datum protection centralize procedure period year mutual recognition procedure depend member state contrast patent list regulatory authority generic version pharmaceutical product approve data protection expire regardless innovator hold patent cover drug possible innovator seek enforce patent generic competitor market product european patent system opposition procedure generic manufacturer challenge validity patent cover innovator product month grant general law treat chemicallysynthesize drug biologicallyderive drug respect intellectual property datum protection addition relevant legislation annexe relate biologic medicinal product ema issue guideline outline additional information provide biosimilar product know generic biologic order review application marketing approval japan japan medicines new chemical entity generally afford year datum exclusivity approve indication dosage patent pharmaceutical product enforceable generic copy receive regulatory approval datum exclusivity patent expiration patent japan extended compensate patent term lose regulatory review process general japanese law treat chemicallysynthesize biologicallyderive drug respect intellectual property market exclusivity rest world country outside japan wide variety legal system respect intellectual property market exclusivity pharmaceutical develop country utilize system similar develop country adopt patent law andor regulatory exclusivity law develop country formally adopt law order comply wto commitment take step implement law meaningful way enforcement wto action long process government assurance outcome assess likely future market exclusivity innovative drug develop country account formal legal right political factor country patent right form exclusivity expire generic version medicine approve market substantial rapid decline sale original innovative product discussion patent right regulatory form exclusivity refer intellectual property product exclusivity discussion impact generic competition business refer generic competition follow chart show key product year early basic exclusivity loss patent right datum exclusivity occur currently estimate occur japan sell pharmaceutical product country datum provide country bycountry basis individual country revenue significant outside japan instance basic exclusivity loss date list expiration date patent claim active ingredient drug method drug approve indication approve indication instance basic exclusivity loss date list chart expiration date datum exclusivity period situation datum exclusivity patent protection competitor seek regulatory approval submit clinical trial datum obtain marketing approval prior expiration datum exclusivity estimate market exclusivity period product purpose business planning length market exclusivity product impossible predict certainty complex interaction patent regulatory form exclusivity inherent uncertainty patent litigation assurance particular product enjoy market exclusivity period time appear estimate exclusivity limited estimate total revenue product past currently estimate year basic exclusivity loss dollar million eua japan oncology empliciti elotuzumabb opdivo nivolumab sprycel dasatinib yervoy ipilimumab cardiovascular eliquis apixaban immunoscience orencia abatacept virology baraclude entecavir hepatitis franchisen reyataz atazanavir sulfate franchise sustiva efavirenz franchise note currently estimate early year basic exclusivity loss include statutory extension exclusivity grant instance able obtain additional month exclusivity product base pediatric extension certain instance laterexpire patent cover particular form composition drug method manufacturing method drug patent result favorable market position product product exclusivity predict assure healthcare law enact qualifying biologic product receive year datum exclusivity biosimilar enter market describe detail intellectual property product exclusivity currently market product country region indicate apotex inc actavis group ptc ehf generics limited mylan unnamed company file opposition epo seek revocation european patent patent cover dasatinib active ingredient sprycel patent schedule expire april exclude potential term extension january opposition division epo revoke patent company appeal epos decision epo board appeal february epo board appeal uphold opposition decision patent revoke experience decline european revenue second half unfavorable epo board appeal decision epo board appeal decision affect validity sprycel patent include different patent cover monohydrate form dasatinib use dasatinib treat chronic myelogenous leukemia cml additionally february epo board appeal reverse remand invalidity decision european patent claim use dasatinib treat cml epos opposition division revoke october intend pursue legal option defend intellectual property right future infringement refer note legal proceeding contingency information reference include member states year end december basic patent application file current member state list product instance date basic exclusivity loss different member states country basic patent obtain datum protection available empliciti commercialization agreement abbvie empliciti information arrangement abbvie refer alliance item financial statementsnote alliance abbvie own composition matter patent cover elotuzumab expire exclude potential patent term extension japan exclude potential patent term extension exclusivity period europe japan base regulatory datum protection opdivo jointly patent ono cover nivolumab composition matter expire exclude potential patent term extension exclude potential patent term extension composition matter patent cover nivolumab japan expire include grant patent term extension sprycel patent term extension grant extend term basic composition matter patent cover dasatinib june company enter settlement agreement apotex patent infringement suit cover monohydrate form dasatinib apotex launch generic dasatinib monohydrate anda product september early certain circumstance yervoy exclusivity period base composition matter patent expire include grant patent term extension datum exclusivity expire patent cover ipilimumab composition matter currently expire exclude potential patent term extension yervoy exclusivity period base regulatory datum protection datum exclusivity expire patent cover ipilimumab composition matter currently expire exclude potential patent term extension patent term extension grant european country country composition matter patent expire yervoy japan exclusivity period base composition matter patent expire include grant patent term extension eliquis composition matter patent cover apixaban expire february request patent term restoration extension pende include potential month pediatric exclusivity extension grant provide protection eliquis japan composition matter patent cover apixaban expire apply supplementary protection certificatesthe supplementary protection certificate european country grant expire datum exclusivity expire composition matter patent cover apixaban japan expire include grant patent term extension orencia series patent cover abatacept method use patent term extension grant composition matter patent extend term patent datum exclusivity expire december method use patent expire orencia composition matter patent covering abatacept expire majority country apply supplementary protection certificate pediatric extension supplementary protection certificate protection december supplemental protection certificate european country grant data exclusivity expire method use patent expire orencia japan exclusivity period base regulatory data protection expire baraclude composition matter patent expire exclusivity period relate daklinza brand composition matter cover daclatasvir japan expire include grant patent term extension reyataz data exclusivity expire market exclusivity project expire sustiva exclusivity period relate sustiva brand include exclusivity relate combination therapy composition matter patent efavirenz expire method use patent treatment hiv infection expire september pediatric exclusivity grant provide additional month period exclusivity add term patent list orange book october company announce successfully resolve outstanding patent litigation relate efavirenz loss exclusivity efavirenz expect occur december joint venture agreement gilead commercialize atripla terminate launch generic version sustiva sustiva exclusivity period relate sustiva brand include exclusivity relate combination therapy market exclusivity sustiva expire november countries data exclusivity sustiva expire research development critical longterm competitiveness major site world operating model evolution geographic footprint significantly transform foster speed innovation future transformation involve close exist site accompany increase investment expansion specifically supplement internal drug discovery development program alliance collaborative agreement help bring new molecular agent capability platform pipeline management continue emphasize leadership innovation productivity quality strategy success activity concentrate effort follow disease area significant unmet medical need oncology include immunoscience cardiovascular fibrotic disease gdd continue analyze selectively pursue promising lead area addition discover develop new molecular entity look way expand value exist product new indication formulation provide additional benefit patient order new drug reach market industry practice government regulation foreign country provide determination drug effectiveness safety preclinical test control clinical evaluation clinical development potential new drug include phase phase phase iii clinical trial design specifically support new drug application particular indication assume trial successful phase clinical trial involve small number healthy volunteer patient suffer indicate disease test safety proper dosing phase clinical trial involve large patient population investigate effect efficacy optimal dosage drug candidate phase iii clinical trial conduct confirm phase result significantly large patient population long term provide reliable conclusive datum safety efficacy drug candidate regulatory approval typically base result phase iii clinical trial times approval grant base datum early trial consider program phase iii significant program program include investigational compound phase iii development initial indication market product phase iii development additional indication formulation drug development time consume expensive risky process typically take fourteen year approximately half year spend phase iii latestage development average chemical compound discover pharmaceutical industry researcher prove medically effective safe approve medicine drug candidate fail stage process latestage product candidate fail receive regulatory approval accord kmr group base industry success rate approximately compound enter phase development fail achieve regulatory approval failure rate compound enter phase development approximately compound enter phase iii development approximately total expense include cost discovery research preclinical development early latestage clinical development drug formulation postcommercialization medical support market product proportionate allocation enterprisewide cost license acquire asset expense billion billion billion include license asset acquisition charge approximately million billion million respectively end employ approximately people relate support activity include substantial number physician scientist hold graduate postgraduate degree higherskille technical personnel manage program portfolio basis invest resource stage early discovery latestage development continually evaluate portfolio asset ensure appropriate balance earlystage latestage program support future growth company spend latestage development program represent approximately annual expense year individual investigational compound market product represent expense year opdivo list investigational compound clinical trial approve potential indication market product relate therapeutic area january list compound ultimately market product depend result clinical study competitive landscape potential product market reimbursement decision payer manufacturing process necessary produce potential product commercial scale factor assurance seek regulatory approval compound approval sought obtain assurance compound get approve commercially successful stage development determine intellectual property issue patent protection available investigational compound january follow potential registrational trial readout opdivo anticipate tumor trial detail tumor trial detail hepatocellular opdivo yervoy opdivo carcinoma nonsmall cell lung cancer opdivo asia opdivo glioblastoma opdivo opdivo standard care small cell lung cancer opdivo yervoy head neck opdivo yervoy nonhodgkin opdivo yervoy opdivo lymphoma melanoma opdivo adjuvant myeloma opdivo empliciti standard care phase renal cell carcinoma opdivo yervoy key phase iii alliance enter alliance party transfer right develop manufacture market andor sell pharmaceutical product own party alliance include licensing arrangement codevelopment comarkete agreement copromotion arrangement joint venture alliance involve share research development cost risk incur research development expense compound lead revenuegenerate product reduce profitability alliance product generally low profit alliance product share alliance partner actively pursue arrangement view alliance important complement discovery development commercialization activity alliance party right manufacture market andor sell pharmaceutical product contain customary early termination provision typically find agreement kind generally base material breach agreement party bankruptcy voluntary involuntary party product safety concern notice require early termination generally range immediately notice day receipt notice termination immediately notice generally available party file voluntary bankruptcy petition material safety issue arise product medical riskbenefit incompatible welfare patient continue develop commercialize product termination notice period generally available involuntary bankruptcy petition file dismiss material breach party occur cure alliance agreement permit terminate cause typically exercisable substantial advance write notice exercisable specify period time elapse alliance agreement sign alliance typically contain provision provide party right terminate alliance general retain right product bring alliance party party intellectual property alliance terminate loss right product market sell pursuant alliance material result operation cash flow material financial condition liquidity customary pharmaceutical industry term alliance generally coextensive exclusivity period vary countrybycountry basis significant alliance currently market product investigational compound describe refer item financial statementsnote alliance additional information alliance agreement alliance agreement pfizer company pfizer party worldwide codevelopment cocommercialization agreement eliquis pfizer fund development cost depend study company share commercialization expense profit loss equally global basis certain country pfizer commercialize eliquis pay bms compensation base percentage net sale gilead joint venture gilead develop commercialize atripla canada europe company gilead share responsibility certain activity relate commercialization atripla canada certain european country gilead recognize atripla revenue canada countries europe alliance revenue recognize atripla include bulk efavirenz component atripla calculate differently follow loss exclusivity sustiva alliance revenue defer relate alliance receivable recognize atripla sell thirdparty customer agreement terminate gilead launch generic version sustiva bms launch generic version truvada individual component loss exclusivity sustiva expect december otsuka bms otsuka alliance sprycel japan oncology territory february copromotion agreement otsuka terminate japan fee pay otsuka base combined annual net sale sprycel ixempra oncology territory maintain commercialization agreement otsuka codevelop copromote abilify limited number country outside ono bms principal end customer product sale exclusive right develop manufacture commercialize opdivo territory worldwide japan south korea taiwan ono entitle receive royalty follow regulatory approval territory exclude country list royalty rate net sale north america applicable territory subject customary adjustment alliance arrangement include collaboration activity japan south korea taiwan pertain opdivo yervoy bms investigational compound party right obligation jointly develop commercialize compound bms responsible supply product profit loss development cost share equally combination therapy involve compound party share activity involve party compound bms ono alliance codevelop cocommercialize orencia japan bms responsible order fulfillment distribution intravenous formulation ono responsible subcutaneous formulation formulation jointly promote party assign customer account bms responsible product supply copromotion fee pay party sale partys assign customer abbvie bms abbvie alliance empliciti term alliance bms grant exclusive global right codevelop commercialize empliciti pdl biopharma inc abbvie party codevelope product abbvie fund global development cost bms solely responsible supply distribution sale marketing activity alliance principal end customer product sale abbvie share profit loss pay tiere royalty net sale empliciti outside addition abbvie entitle receive milestone payment bms certain regulatory event sale threshold achieve licensing arrangement addition alliance describe inlicense outlicense arrangement respect inlicense agreement novartis reyataz merck efavirenz certain compound outlicense party development commercialization include obtain acquisition entitle receive milestone payment compound regulatory process royalty base net product sale product commercialize marketing distribution customer promote appropriate use product directly healthcare professional provider doctor nurse practitioner physician assistant pharmacist technologist hospital pbms mco provide information appropriate use product consumer directtoconsumer print radio television digital advertising promotion addition sponsor general advertising educate public innovative medical research corporate mission discussion regulation promotion marketing pharmaceutical refer government regulation field sale medical organization explain risk benefit approve use product medical professional work gain access product formulary reimbursement plan list recommend approve medicine product include medicare plan provide information clinical profile product marketing sale prescription pharmaceutical limit approve use particular product continue develop scientific datum information potential additional use product provide information response unsolicite inquiry doctor medical professional mcos operation include marketing sale organization product marketing organization support sale force responsible sell product market organization focus certain class customer manage care entity certain type marketing tool digital consumer communication sale force focus communicate information new product new use establish product promotion physician increasingly target physician specialist treat patient need medicine product sell principally wholesaler less extent directly distributor retailer hospital clinic government agency pharmacy refer item financial statementsnote business segment information gross revenue large pharmaceutical wholesaler percentage global gross revenue business ima substantially direct wholesaler distributor customer allow monitor wholesaler inventory level require wholesaler distributor maintain inventory level month demand ima include large wholesaler expire december subject certain termination provision nonus business significantly direct customer information available direct customer product level inventory correspond movement information reliability thirdparty demand information vary widely limit direct customer sale channel inventory report reliably gather report inventory level customer number country outside contract distributor support certain product service provide distributor vary market include distribution logistic regulatory pharmacovigilance andor sale advertising promotion sale distributorbase country represent approximately company total revenue competition market compete generally broad base highly competitive compete worldwide researchbase drug company small research company limit therapeutic focus generic drug manufacturer important competitive factor include product efficacy safety ease use price demonstrate costeffectiveness marketing effectiveness product label customer service new product process sale product impact new study indicate competitor product safe effective treat disease particular form disease product revenue impact additional labeling requirement relate safety convenience impose product fda similar regulatory agency different country competitor introduce new product process therapeutic cost advantage product subject progressive price reduction decrease volume sale generic competition big competitive challenge face generic pharmaceutical manufacturer regulatory approval process exempt generic costly timeconsuming clinical trial demonstrate safety efficacy allow generic manufacturer rely safety efficacy innovator product result generic pharmaceutical manufacturer typically invest far researchbase pharmaceutical company price product significantly lower brand product accordingly brand product lose market exclusivity normally face intense price competition generic form product expiration loss market exclusivity product lose major portion revenue product short period time rate revenue decline product expiration exclusivity vary country general decline market rapid develop country observe rapid decline number country decline develop country tend rapid develop country rate revenue decline expiration exclusivity historically influence product characteristic example drug large patient population prescribed key primary care physician tend experience rapid decline drug specialized area medicine oncology drug complex manufacture sterile injectable product usually experience slow decline simple manufacture certain country outside patent protection weak nonexistent compete generic version shortly launch innovative product addition generic pharmaceutical company introduce generic product exclusivity expire resolution relate patent litigation information market exclusivity refer intellectual property product exclusivity believe longterm competitive position depend success discover develop innovative costeffective product serve unmet medical need ability manufacture product efficiently market effectively highly competitive environment pricing price constraint market access medicine price base number factor include value scientific innovation patient society context overall health care spend economic factor impact health care system ability provide appropriate sustainable access necessity sustain investment innovation platform address unmet medical need central price clinical value innovation bring market current landscape alternative treatment option goal ensure appropriate patient access innovation sustain investment creative platform continue explore new pricing approach ensure patient access medicine enhance patient access medicine priority focus offer creative tiere pricing voluntary licensing reimbursement support patient assistance program optimize access protect innovation advocate sustainable healthcare policy infrastructure leverage advocacypayer input utilize partnership appropriate improve access care supportive service vulnerable patient partnership demonstration project growth mcos major factor healthcare marketplace half population participate version manage care mco include medical insurance company medical plan administrator healthmaintenance organization medicare prescription drug plan alliance hospital physician physician organization organization consolidate few large entity enhance purchasing strength importance successfully compete business mcos demonstrate product offer medical benefit cost advantage compare form care new product introduce compete product market product later develop competitor note generic drug exempt costly timeconsuming clinical trial demonstrate safety efficacy lower cost brandname drug mcos focus primarily immediate cost drug favor generic reason government encourage use generic alternative brandname drug healthcare program law generally allow case require pharmacist substitute generic drug rate government procedure essentially equivalent brandname drug substitution prescribe physician expressly forbid exclusion product formulary lead sharply reduce usage mco patient population consequently pharmaceutical company compete aggressively product include possible company compete inclusion base unique feature product great efficacy well patient ease use few effect low overall cost therapy important factor product demonstrate few therapeutic advantage compete inclusion base primarily price generally universally successful major product include mco formulary market outside operate environment governmentmandate costcontainment program market significant portion fund healthcare service determination pricing reimbursement pharmaceutical product subject government control result product face restrict access public private payer subject assessment comparative value effectiveness competitive product government place restriction physician prescription level patient reimbursement emphasize great use generic drug andor enact acrosstheboard price cut method cost control countries example government regulate price new product launch direct price control international price comparison control profit andor reference pricing market germany government set pricing restriction launch pricing freedom subsequently limit company face significant delay market access new product mainly france spain italy belgium year elapse new medicine available national market additionally member states regularly impose new additional cost containment measure pharmaceutical volume discount cost cap cost sharing increase excess prior year cost individual product aggregate market level spend outcomebase pricing scheme free product portion expect therapy period recent year italy example impose mandatory price decrease existence price differential different national pricing reimbursement law lead significant parallel trade flow government regulation pharmaceutical industry subject extensive global regulation regional country state local agency federal food drug cosmetic act federal statute regulation state statute regulation law regulation foreign government govern vary degree test approval production labeling distribution postmarket surveillance advertising dissemination information promotion product lengthy process laboratory clinical testing datum analysis manufacture development regulatory review necessary require governmental approval extremely costly significantly delay product introduction give market promotion marketing manufacturing distribution pharmaceutical product extensively regulate major world market addition operation subject complex federal state local foreign environmental occupational safety law regulation anticipate law regulation affect manufacture sale current product introduction new product continue require substantial scientific technical effort time expense significant capital investment particular importance fda jurisdiction virtually activity impose requirement cover testing safety effectiveness manufacturing labeling marketing advertising postmarkete surveillance product case fda requirement increase time money necessary develop new product bring market fda mandate drug manufacture package label conformity cgmp establish fda comply cgmp regulation manufacturer continue expend time money effort production recordkeeping quality control ensure product meet applicable specification requirement ensure product safety efficacy fda periodically inspect drug manufacturing facility ensure compliance applicable cgmp requirement failure comply statutory regulatory requirement subject possible legal regulatory action suspension manufacturing seizure product voluntary recall product adverse experience use product report fda result imposition market restriction label change product removal product approval withdraw compliance regulatory requirement maintain problem concern safety efficacy occur follow approval federal government extensive enforcement power activitie pharmaceutical manufacturer include authority withdraw delay product approval commence action seize prohibit sale unapproved noncomplye product halt manufacture operation compliance cgmp impose seek injunction voluntary recall civil monetary criminal penalty restriction prohibition sale withdrawal approval product market materially adversely affect business financial condition result operation cash flow marketing authorization product subject revocation applicable governmental agency addition modification enhancement approve product change manufacturing location circumstance subject additional fda approval receive subject lengthy application process distribution pharmaceutical product subject pdma federal food drug cosmetic act regulate activity federal state level pdma implement regulation state permit require registration manufacturer distributor provide pharmaceutical manufacturer distributor place business state state permit adopt regulation limit distribution product sample license practitioner pdma impose extensive licensing personnel recordkeeping packaging quantity labeling product handle facility storage security requirement intend prevent sale pharmaceutical product sample product diversion fda amendment act impose additional obligation pharmaceutical company delegate enforcement authority fda area drug safety key element legislation fda authority require company conduct postmarkete safety study drug impose certain drug labeling change relate safety mandate risk mitigation measure education healthcare provider restrict distribution medicine require company publicly disclose datum clinical trial prereview television advertisement marketing practice pharmaceutical manufacturer subject federal state healthcare law protect integrity government healthcare program oig oversee compliance applicable federal law connection payment product government fund program primarily medicaid medicare law include federal antikickback statute criminalize offer value induce recommendation order purchase product service reimburse government healthcare program oig issue series guidance segment healthcare industry include compliance program guidance pharmaceutical manufacturer include recommendation pharmaceutical manufacturer minimum adhere phrma code voluntary industry code marketing practice subscribe phrma code implement compliance program address requirement set forth guidance compliance healthcare law failure comply healthcare law subject administrative legal proceeding include action federal state government agency action result imposition civil criminal sanction include fine penalty injunctive remedy impact materially adversely affect business financial condition result operation cash flow subject jurisdiction federal state regulatory enforcement department agency federal trade commission department justice department health human service license drug enforcement agency procure produce control substance subject possible administrative legal proceeding action organization action result imposition civil criminal sanction include fine penalty injunctive administrative remedy healthcare industry subject governmentimposed regulation authorize price price control continue impact total revenue participate state government medicaid program certain qualify federal state government program discount rebate provide participate state local government entity participate government program specify discount certain government entity significant department defense department veterans affair entity receive minimum discount base define nonfederal average manufacturer price purchase result patient protection affordable care act reconciliation bill contain package change healthcare bill experience continue experience additional financial cost certain change business example minimum rebate medicaid drug sale increase percent percent medicaid rebate extend drug riskbase medicaid manage care plan addition extend discount certain critical access hospital cancer hospital cover entity require expansion drug pricing program public health service act require provide percent discount brandname drug patient fall medicare coverage gap refer donut hole pay annual nontaxdeductible fee federal government base allocation market share brand drug sale certain government program include medicare medicaid department veterans affairs department defense tricare activity outside subject regulatory requirement govern testing approval safety effectiveness manufacturing labeling marketing product regulatory requirement vary country country fda approval approval obtain product approval product comparable regulatory authority country outside case obtain prior marketing product country approval process rigorous country country time require approval long shorter require approval country assure product approve country discussion rebate program refer item management discussion analysis financial condition result operation total revenue critical accounting policy sources availability raw material general purchase raw material supply require production product open market product purchase raw material supply source source available single source approve source available require obtain raw material supply particular source attempt possible mitigate raw material supply risk inventory management alternative source strategy discussion source refer manufacture quality assurance discussion particular product manufacture quality assurance operate manage manufacturing network manner permit improve efficiency maintain flexibility reallocate manufacturing capacity pharmaceutical production process complex highly regulate vary widely product product give shift add manufacturing capacity lengthy process require significant capital expenditure regulatory approval maintain operate flexible manufacturing network consist internal external resource minimize unnecessary product transfer inefficient use manufacturing capacity discussion regulatory impact manufacturing refer government regulation price constraint pharmaceutical manufacturing facility locate puerto rico france italy ireland japan china require significant ongoing capital investment maintenance compliance increase regulatory requirement addition product line change year expect continue modification exist manufacturing network meet complex processing standard require newly introduce product include biologic biologic manufacturing involve complex process traditional pharmaceutical operation fda approve large scale multiproduct bulk biologic manufacturing facility deven massachusetts continue capital investment facility build new largescale biologic manufacturing facility cruiserath ireland rely party manufacture supply portion active ingredient necessary manufacture product opdivo sprycel yervoy eliquis orencia baraclude reyataz sustiva franchise maintain stable supply product variety action include inventory management maintenance additional quantity material possible design provide reasonable level ingredient hold thirdparty supplier manufacturing operation interrupt additional protection case step maintain approve backup source available example rely capacity devens massachusetts facility capacity available thirdparty contract manufacturer manufacture orencia connection divestiture license arrangement distribution agreement certain product certain circumstance enter agreement agree supply product party addition liability arise failure supply product agreement arrangement require invest facility production nonstrategic product result additional regulatory filing obligation cause interruption manufacturing product success depend great measure customer confidence quality product integrity datum support safety effectiveness product quality arise total commitment quality part operation include research development purchasing facility planning manufacturing distribution maintain qualityassurance procedure relate quality integrity technical information production process control production process involve detailed specification ingredient equipment facility manufacturing method process packaging material labeling perform test stage production process final product ensure product meet regulatory requirement standard test involve chemical physical chemical analyse microbiological testing combination analyse quality control provide business unitsite quality assurance group monitor exist manufacturing procedure system subsidiary thirdparty supplier environmental regulation facility operation subject extensive foreign law regulation relate environmental protection human health safety include govern discharge pollutant air water use management disposal hazardous radioactive biological material waste cleanup contamination pollution control permit require operation permit subject modification renewal revocation issue authority environment health safety group monitor operation world provide overview regulatory requirement oversee implementation standard compliance incur operating capital cost matter ongoing basis material addition invest project reduce resource use energy water believe substantial compliance applicable environmental health safety requirement permit require operation incur additional cost include civil criminal fine penalty cleanup cost thirdparty claim property damage personal injury violation liabilitie law current facility operation year time operator facility generate store dispose substance waste consider hazardous federal state andor foreign environmental law include cercla result soil groundwater certain facility contaminate require significant expenditure investigate control remediate contamination case provide compensation andor restoration damage natural resource currently involve investigation remediation current facility identify prp applicable law environmental condition approximately waste disposal reprocess facility operate party investigation andor remediation activity ongoing face liability cercla federal state foreign law entire cost investigation remediation contaminate site natural resource damage regardless fault ownership time disposal release addition certain site bear remediation responsibility pursuant contractual obligation generally thirdparty operator site involve multiple prps liability expect apportion base nature hazardous substance dispose party site number financially viable prps additional information matter refer item financial statementsnote legal proceeding contingency employee approximately employee december foreign operation significant operation outside conduct subsidiary distributor international operation subject certain risk inherent conduct business abroad include limited currency fluctuation possible nationalization expropriation price exchange control counterfeit product limitation foreign participation local enterprise restrictive governmental action international business subject governmentimpose constraint include law price reimbursement use product bristolmyer squibb website internet website address wwwbmscom website available free charge annual quarterly current report include amendment report soon reasonably practicable electronically file material furnish material sec information relate corporate governance bristolmyer squibb include principle integrity code ethic senior financial officer code business conduct ethic director collectively code corporate governance guideline information concern executive committee board director include board committee committee charter transaction bristolmyers squibb security director executive officer available website investorscorporate governance caption print stockholder request waiver code director executive officer material amendment code business conduct ethic director code ethic senior financial officer post promptly website information relate stockholder service include dividend reinvestment plan direct deposit dividend available website investorsstockholder service caption addition information sustainability program available website responsibility caption incorporate reference certain information part proxy statement annual meeting stockholder sec allow disclose important information refer manner refer information proxy statement annual meeting stockholder annual report available website investorssec filing caption march item risk factor factor describe significantly negatively affect business prospect financial condition operating result credit rating cause trading price common stock decline additional risk uncertainty presently know risk currently consider immaterial impair operation financial condition public announcement datum clinical study competitor news development relate competitor product latestage compound cause significant volatility stock price depend news result adverse impact business financial condition result operation development key compound combination therapy delay discontinued stock price decline significantly adverse impact business financial condition result operation focus effort resource certain disease area focus portfolio investor place heighten scrutiny product latestage compound particular opdivo important asset portfolio announce multiple regulatory milestone opdivo encounter significant setback firstline lung cancer announcement negative result checkmate announce pursue accelerate regulatory pathway combination opdivoyervoy negative impact stock price expect receive news ongoing clinical trial health authority new potential indication announcement datum clinical study competitor news development relate competitor product latestage compound opdivo cause significant volatility stock price depend news result adverse impact business financial condition result operation furthermore announcement negative unexpected datum discontinuation development key compound combination therapy delay anticipate timeline file regulatory approval significant advancement competitor cause stock price decline significantly adverse impact business financial condition result operation assurance datum clinical study support filing regulatory approval key compound prove effective effective compete compound approve key compound commercially successful approve indication depend key product revenue cash flow earning historically derive majority revenue earning key product heavily dependent product past year dependence profitability certain product likely continue expect growth product opdivo eliquis increasingly important revenue base reduction revenue product adverse impact revenue cash flow earning experience difficulty delay development commercialization new product compound product appear promise development fail reach market expected optimal timeframe addition product extension additional indication approve develop commercialize new compound product include inherent risk uncertainty include efficacy safety concern delay deny regulatory approval delay challenge produce product commercial scale excessive cost manufacture failure enter implement optimal alliance development andor commercialization new product iii failure maintain consistent scope variety promise latestage product failure product achieve maintain commercial viability change regulatory approval process cause delay denial new product approval regulatory approval delay especially common product expect risk evaluation mitigation strategy require fda address significant riskbenefit issue inability bring product market significant delay expect approval relate launch date new product negatively impact revenue earning addition certain acquire pipeline program include iprd cancel believe commercial prospect reduce recognize material noncash impairment charge program finally lose key molecule intermediary compound library natural manmade disaster act sabotage negatively impact product development cycle face intense competition manufacturer include innovative medicine lowerprice generic product bms dependent market access uptake expansion market brand new product introduction new indication product extension promotional activity alliance partner deliver future growth competition keen include lowerprice generic increasingly aggressive generic commercialization tactic low price company product real perceive superior efficacy benefit safety risk profile differentiate factor iii technological advance patent attain competitor clinical study result product competitor product affect value proposition product business combination competitor major thirdparty payer compete interest external partnership develop bring new product market unable compete successfully competitor product marketplace material negative impact revenue earning litigation claim infringement intellectual property adversely affect future revenue operate earning party claim infringe intellectual property resolve intellectual property infringement claim costly time consuming require enter license agreement available commercially reasonable term successful claim patent intellectual property infringement subject significant damage injunction prevent manufacture sale use affect product product event material adverse effect profitability financial condition adverse outcome legal matter negatively affect business current future lawsuit claim proceeding government investigation preclude delay commercialization product adversely affect operation profitability liquidity financial condition possible insurance recovery available legal matter include intellectual property dispute adverse decision litigation include product liability commercial case iii antibribery regulation foreign corrupt practice act bribery act include compliance ongoe reporting obligation government result settlement recall withdrawal pharmaceutical product force closing manufacture plant failure fulfill obligation supply contract government customer product pricing promotional matter vii lawsuit claim assert investigation violation security antitrust federal state pricing consumer protection datum privacy law viii environmental health safety sustainability matter tax liability result assessment tax authority lose market exclusivity product early expect pharmaceutical biotechnology industry majority innovative product commercial value realize market exclusivity period country market exclusivity expire generic version approve market biosimilar introduce compete product usually substantial rapid decline product revenue market exclusivity product base patent right certain regulatory form exclusivity scope patent right vary country country dependent availability meaningful legal remedy country failure obtain patent intellectual property right limitation use loss right material country include certain member state basic patent protection product exist certain country historically offer right obtain specific type patent andor licensor file country addition patent environment unpredictable validity enforceability patent predict certainty absent relevant patent protection product datum exclusivity period expire generic version approve market generic biosimilar product manufacturer group seek financial gain increasingly seek challenge patent expire face earlierthanexpecte competition product time patent cover key product likely continue subject patent litigation example february patent sprycel revoke opposition division epo result experience decline european revenue second half refer item financial statementsnote legal proceeding contingency information case manufacturer seek regulatory approval submit clinical trial datum obtain marketing approval choose launch generic product risk expiration applicable patent andor final resolution relate patent litigation assurance particular product enjoy market exclusivity time period appear estimate disclose assume provide financial guidance addition country india allow competitor manufacture sell compete generic product negatively impact protection afford company lowerprice biosimilar bms biologic product compete biologic negatively impact volume price increase pricing pressure restriction abroad mcos institutional purchaser government agency program negatively affect revenue profit margin product continue subject increase pressure portfolio market access pricing discount restriction region world include rule practice mcos institutional governmental purchasers judicial decision change law regulation federal healthcare program medicare medicaid government action inquiry iii potential impact change pharmaceutical reimbursement increase pricing pressure medicare formulary medicare reimbursement rate physician commercial formulary general reimbursement delay government price erosion mechanism europe country result deflation pharmaceutical product pricing collection delay failure pay governmentfunde public hospital outside vii impact pricing parallel trade border viii development technology andor industry practice impact reimbursement policy practice thirdparty payer inhibited market access real perceive difference value proposition product compare compete product change foreign law regulation include tax regulation negatively affect revenue profit margin subject new government law regulation negatively affect business operating result financial condition company additional healthcare reform initiative country include additional mandatory discount fee change tax rate change tax base include limit phasingout eliminate deduction tax credit tax certain excess income intellectual property change rule earning repatriation change tax law countrie iii new law regulation judicial governmental decision affect pricing drug reimbursement receivable payment access marketing jurisdiction change intellectual property law change accounting standard increase datum privacy regulation enforcement vii emerge new global regulatory requirement report payment value transfer healthcare professional viii potential impact importation restriction legislative andor regulatory change thirdparty royalty represent significant percentage pretax income operate cash flow enter arrangement entitle potential royalty party outlicense intellectual property commercialization right salesbase contingent proceed relate divestiture business arrangement minimal continue involvement contribute financial success activity royalty continue represent significant percentage pretax income include royalty relate divestiture diabete business include transfer certain future royalty right pertain amylin product sale sanofi alliance outlicense intellectual property contingent proceed result erbitux business pretax income generate royalty approximately billion pretax income adversely affect royalty stream decline future period failure execute business strategy adversely impact growth profitability strategy focus deliver innovative transformational medicine patient unable successfully execute strategy negatively impact future result operation market capitalization connection strategy recently announce evolution operating model focus investment commercial opportunity key brand market accelerate pipeline streamline operation realign manufacturing capability broaden biologic capability thing ability successfully execute operating model evolution impact result example able achieve cost saving expect negatively impact operate margin earning result addition able consistently maintain rich pipeline internal program transaction party support future revenue growth competition pharmaceutical company acquisition product licensing opportunity intense able locate suitable acquisition target license partner reasonable price successfully execute transaction unable support grow market product successfully execute launch newly approve product advance latestage pipeline manage change operating model evolution issue manage cost effectively operate result financial condition negatively impact failure attract retain highly qualified personnel affect ability successfully develop commercialize product success largely dependent continue ability attract retain highly qualified scientific technical management personnel personnel expertise clinical governmental regulation commercialization competition qualified personnel biopharmaceutical field intense sure able attract retain quality personnel cost materially increase business asset acquire future underperform able successfully integrate exist business continue support pipeline compound product obtain licensing acquisition future revenue profit cash flow acquire company product technology pipeline candidate materialize low product uptake delay miss pipeline opportunity inability capture expect synergy increase competition safety concern regulatory issue supply chain problem factor control substantial difficulty cost delay result integrate acquisition include manufacturing distribution sale marketing promotion information technology activity policy procedure process control compliance iii company culture compensation structure human resource activity tax consideration experience difficulty delay manufacture distribution sale product product supply relate patient access negatively impact thing product seizure recall force closing manufacture plant failure failure supplier comply cgmp applicable regulation quality assurance guideline lead manufacturing shutdown product shortage delay product manufacture iii manufacturing quality assurancequality control supply problem governmental approval delay failure sole source single source supplier provide necessary raw material supply finish good reasonable timeframe require quality failure thirdparty manufacturer supply bulk active finished product time construction regulatory approval delay new facility expansion exist facility include intended support future demand biologic product opdivo vii failure meet new emerge regulation require product track distribution channel unique identifier verify authenticity supply chain viii manufacturing distribution issue include limit manufacturing capacity change type product produce biologic physical limitation business interruption disruption supply chain continuity include natural disaster act war terrorism external factor control impact facility critical supplier product labeling change market product result negative impact revenue profit margin regulatory authority need change label pharmaceutical product include product market year change result additional datum postmarkete study headtohead trial adverse event report study identify biomarker objective characteristic indicate particular response product therapy study postmarkete experience produce important additional information product new information add product label affect riskbenefit profile lead potential recall withdrawal decline revenue product liability claim additional information study identify portion patient population nonresponsive medicine high risk adverse reaction label change base study limit patient population study provide additional information sponsor sponsor competitor insurance company government institution manage care organization scientist investigator interested party additional safety efficacy information study assist healthcare provider identify good patient population product negatively impact revenue inventory return limit patient population go forward additionally certain study result especially headtohead trial affect product formulary listing adversely affect revenue failure party meet contractual regulatory obligation adversely affect business rely supplier vendor outsource partner alliance partner party research develop manufacture commercialize copromote sell product manage certain marketing sell human resource finance business unit functional service meet contractual regulatory obligation party pose number risk perform standard legal requirement produce reliable result iii perform timely manner maintain confidentiality proprietary information dispute arise respect ownership right technology develop partner disagreement cause delay termination research development commercialization product result litigation arbitration party locate market subject political social risk corruption infrastructure problem natural disaster addition country specific privacy datum security risk give current legal regulatory environment failure critical party meet obligation include future royalty milestone payment adequately deploy business continuity plan event crisis andor satisfactorily resolve significant disagreement address factor material adverse impact operation result addition party violate allege violate law regulation include local pharmaceutical code foreign corrupt practice act bribery act similar law regulation performance obligation possible suffer financial reputational harm negative outcome include possible legal consequence illegal distribution sale party counterfeit version product steal product negative impact reputation business party illegally distribute sell counterfeit version product meet rigorous manufacturing testing standard patient receive counterfeit drug risk number dangerous health consequence reputation business suffer harm result counterfeit drug sell brand addition theft inventory warehouse plant intransit properly store later sell unauthorized channel adversely impact patient safety reputation business dependent information technology system infrastructure face certain risk include cybersecurity breach datum leakage rely extensively system network service include internet site data host processing facility tool physical security system hardware software technical application platform manage host provide andor thirdpartie vendor assist conduct business significant breakdown invasion corruption destruction interruption critical information technology system infrastructure workforce authorize access system unauthorized person negatively impact operation everincrease use evolution technology include cloudbase computing create opportunity unintentional dissemination intentional destruction confidential information store thirdparty provider system portable medium storage device experience business interruption theft confidential information reputational damage industrial espionage attack malware cyberattack compromise system infrastructure lead datum leakage internally thirdparty provider aggregate impact operation financial condition material date target event nature expect continue cybersecurity threat rapidly evolve sophistication prevalent industry invest industry appropriate protection monitor practice datum reduce risk continue monitor system ongoing basis current potential threat assurance effort prevent breakdown breach thirdparty provider database system adversely affect business increase use social medium platform present risk challenge increase use social medium communicate company news event inappropriate andor unauthorized use certain medium vehicle cause brand damage information leakage lead legal implication include improper collection andor dissemination personally identifiable information employee patient healthcare professional stakeholder addition negative inaccurate post comment social network website damage reputation brand image goodwill disclosure nonpublic companysensitive information workforce external medium channel lead information loss identify new point entry social medium continue expand present new challenge adverse change global regional local economic condition adversely affect profitability global economic risk pose significant challenge company growth profitability difficult mitigate generate approximately revenue outside revenue earning cash flow expose risk strengthen dollar world major economy hold historicallyhigh debt level experience slow growth high unemployment rate exposure customer credit risk europe south america market include governmentguaranteed hospital receivables market payment receive time significant operation europe include manufacture distribution result operation negatively impact member country exit eurozone monetary union include exit addition future pension plan funding requirement continue sensitive global economic condition relate impact equity market guarantee pay dividend repurchase stock declaration time dividend fall discretion board director board decision depend factor include financial condition earning capital requirement debt service obligation industry practice legal requirement regulatory constraint factor board director deem relevant reduction elimination dividend payment dividend program adversely affect stock price addition time decide buy share market adversely affect stock price item unresolved staff comment item property principal executive office locate park avenue new york lease approximately property world manufacturing administration storage distribution believe manufacturing property combination thirdparty manufacturer provide adequate production capacity current operation information manufacturing property refer item businessmanufacture quality assurance significant manufacturing location geographic area follow december manufacturing united states europe total item legal proceeding information pertain legal proceeding find item financial statementsnote legal proceeding contingency incorporate reference item safety disclosure applicable executive officer registrant list information executive officer february executive officer elect board director initial term continue board meeting follow annual meeting stockholder elect oneyear term successor elect executive officer serve discretion board director current position age employment history past year giovanni caforio president pharmaceutical chief executive officer director executive vice president chief commercial officer member leadership team chief operating officer director company present chief executive officer director company charle bancroft chief financial officer executive vice president global services chief financial officer executive vice president present chief financial officer executive vice president global business global business operation operation member leadership team emmanuel blin president general manager japan senior vice president chief strategy officer president global commercialization member leadership team senior vice president head commercialization policy operation present senior vice president chief strategy officer joseph caldarella present senior vice president corporate controller senior vice president corporate controller francis cuss bchir frcp senior vice president research executive vice president chief scientific officer present executive vice president chief scientific officer member leadership team john elicker present senior vice president public affairs investor relation senior vice president public affairs investor relation member leadership team murdo gordon senior vice president oncology immunology executive vice president chief commercial officer president pharmaceuticals member leadership team senior vice president head worldwide market present executive vice president chief commercial officer ann powell judge chief human resource officer shire pharmaceutical senior vice president chief human resource senior vice president global human resource officer present senior vice president chief human resource officer member leadership team sandra leung general counsel corporate secretary executive vice president general counsel executive vice president general counsel corporate secretary member leadership team present executive vice president general counsel anne nielsen vice president associate general counsel senior vice president chief compliance ethic senior vice president deputy general counsel officer present senior vice president chief compliance ethic officer member leadership team louis schmukler present president global manufacturing supply president global manufacturing supply member leadership team paul von autenrie senior vice president chief information officer senior vice president chief information officer senior vice president enterprise service chief information officer member leadership team present senior vice president chief information officer item market registrant common stock stockholder matter market price bristolmyer squibb common stock trade nyse symbol bmy quarterly summary high low closing market price present high low high low common quarter second quarter quarter fourth quarter holder common stock number record holder common stock december number record holder base actual number holder register book date include holder share street name person partnership association corporation entity identify security position listing maintain depository trust company dividend board director declare follow quarterly dividend share pay period indicate common prefer quarter second quarter quarter fourth quarter december board director declare quarterly dividend share common stock pay february shareholders record january board director declare quarterly dividend share prefer stock payable march shareholders record february unregistere sale equity security use proceed follow table summarize surrender equity security month period end december total number share approximate dollar value average price purchase share total number pay publicly announce purchase period share purchaseda sharea programsb programsb dollar million share datum january february march month end march april june month end june july august september month end september october november december month end december month end december include share repurchase publicly announce program share common stock surrender company satisfy tax withholding obligation connection vest award longterm incentive program board director authorize repurchase billion common stock june increase authorization repurchase common stock additional billion october board director approve new share repurchase program authorize repurchase additional billion common stock stock repurchase program expiration date item select financial datum year financial summary amount million share datum income statement dataa total revenue continue operation net earning net earning attributable noncontrolle interest bms net earning common share attributable bms basic diluted average common share outstanding basic diluted cash dividend pay bms common prefer stock cash dividend declare common share financial position datum december cash cash equivalent marketable securitiesb total asset longterm debtb equity discussion item affect comparability result year refer item management discussion analysis financial condition result operationsnongaap financial measure include current noncurrent portion item management discussion analysis financial condition result operation executive summary bristolmyers squibb company global specialty biopharmaceutical company mission discover develop deliver innovative medicine help patient prevail disease refer summary abbreviate term end term document receive approval new medicine additional indication formulation currently market medicine major market japan announce multiple regulatory milestone achievement opdivo encounter significant setback firstline lung cancer announcement negative result checkmate announce pursue accelerate regulatory pathway opdivoyervoy combination therapy firstline lung cancer pursue broad program firstline lung cancer encompass combination opdivoyervoy opdivo chemotherapy opdivo combine yervoy chemotherapy commit investigate opdivo combination yervoy anti cancer agent tumor type continue believe breadth depth portfolio position future new compound clinical development trial different tumor type october announce evolution operating model discuss strategy revenue increase result high opdivo eliquis orencia product sale impact partially offset expiration commercialization right abilify transfer erbitux right north america increase competition reyataz sustiva baraclude certain market increase gaap eps high revenue divestiture gain royalty low license asset acquisition charge partially offset high eliquis profit sharing opdivo relate expense tax impact specify item earning mix contribute change effective tax rate adjust divestiture gain license asset acquisition charge specify item nongaap eps increase highlight follow table summarize financial information year end december dollar million share datum total revenue total expense earning income taxis provision income taxis effective tax rate net earning attributable bms gaap nongaap dilute earning share gaap nongaap cash cash equivalent marketable security nongaap financial measure include nongaap earning relate eps information adjust exclude specify item represent certain cost expense gain loss item impact comparability financial result detail list specify item information reconciliation nongaap financial measure refer nongaap financial measure significant product pipeline approval follow summary significant approval receive product date approval jmhlw manufacturing marketing approval treatment relapse refractory chl receive december alliance partner ono approval treatment adult patient relapse refractory chl asct treatment november brentuximab vedotin fda approval treatment patient scchn disease progression platinumbase november therapy jmhlw manufacturing marketing approval treatment unresectable metastatic rcc receive opdivo august alliance partner ono fda approval treatment patient chl relapse progress autohsct posttransplantation brentuximab vedotin april approval treatment previously treat rcc april approval treatment previously treat patient metastatic nsq nsclc jmhlw manufacturing marketing approval treatment previously untreated unresectable february melanoma approval treatment unresectable metastatic melanoma regardless braf mutational status opdivo fda expand use treatment previously untreated unresectable metastatic melanoma regardless yervoy january braf mutational status jmhlw manufacturing marketing approval combination revlimid dexamethasone september treatment multiple myeloma empliciti approval treatment multiple myeloma combination therapy revlimid dexamethasone patient receive prior therapy approval combination mtx treatment highly active progressive disease adult september patient previously treat mtx orencia announce commercial launch orencia clickject autoinjector new selfadministere july autoinjector adult moderate severe announce commercial launch japan orencia clickject autoinjector adult moderate severe jmhlw manufacturing marketing approval ximency combination tablet contain daclatasvir december asunaprevir beclabuvir treatment hcv genotype fda approval daklinza use sofosbuvir treatment chronic hcv genotype hepatitis franchise february additional patient population approval daklinza use sofosbuvir treatment chronic hcv new patient january population approval reyataz oral powder indicate hivinfecte child month optimize reyataz june reyataz capsule pediatric dose recommendation refer product pipeline development development market product latestage pipeline strategy focus specialty biopharmaceutical company discover develop deliver transformational medicine address unmet medical need strategy combine resource scale capability pharmaceutical company speed focus innovation biotech industry strategic priority drive business performance continue build strong franchise maintain diversified portfolio outside continue discipline approach capital allocation include establish partnership collaboration essential component successfully deliver transformational medicine patient develop new medicine follow core therapeutic area oncology include immunoscience cardiovascular fibrotic disease gdd continue invest new study monotherapy combination therapy new molecule mechanism action deliver promise new treatment option patient lung cancer quickly possible continue priority company continue invest significantly deep pipeline innovative medicine cover broad array cancer enter collaboration agreement research develop opdivo approve investigational oncology agent combination regimen include yervoy remain focused wellresource firstline lung development program continuously look way strengthen broad portfolio bring forward new treatment cancer continue strengthen early stage portfolio immunoscience cardiovascular fibrotic disease internally partnership diverse group company academic institution new expand research activity believe internal external focus differentiate contribute transformation portfolio commercial model continue evolve market product portfolio grow manner consistent overall strategy continue drive growth opdivo expand additional indication tumor type monotherapy combination yervoy anticancer agent opdivo yervoy build continue success remain strongly commit eliquis orencia sprycel commercial infrastructure uniquely leverage potential growth announce plan multiyear evolution operating model focus commercial resource key brand market deliver lean administrative function streamline manufacture network reflect importance biologic current future portfolio new operating model enable deliver strategic financial operational flexibility necessary invest high priority look ahead continue implement biopharma strategy drive growth key brand execute product launch invest diverse innovative pipeline include business development focus prioritize market increase investment biologic manufacturing capability maintain culture continuous improvement acquisition licensing arrangement acquisition licensing transaction allow focus resource growth opportunity drive great longterm value focus follow core therapeutic area oncology include immunoscience cardiovascular fibrotic disease significant transaction enter summarize nitto denko december bms nitto denko enter exclusive worldwide license agreement grant bms right develop commercialize nitto denko investigational sirna molecule target hsp vitamin contain formulation include nitto denko lead asset ndls currently phase study treatment advance liver fibrosis agreement grant bms option receive exclusive license hsp sirnas vitamin contain formulation treatment lung fibrosis organ fibrosis cormorant july bms acquire outstanding share cormorant private pharmaceutical company focus development therapy cancer rare disease acquisition provide bms right cormorant lead candidate humaxil phase iii monoclonal antibody represent potentially complementary mechanism action tcell direct antibodie costimulatory molecule padlock april bms acquire outstanding share padlock private biotechnology company dedicate create new medicine treat destructive autoimmune disease acquisition provide bms right padlock pad inhibitor discovery program focus development potentially transformational treatment approach patient rheumatoid arthritis padlock pad discovery program additional utility treat systemic lupus erythematosus autoimmune disease portola february bms pfizer enter collaboration license agreement portola develop commercialize investigational agent andexanet alfa japan andexanet alfa design reverse anticoagulant activity factor inhibitor include eliquis bms pfizer responsible development regulatory activity andexanet alfa japan exclusively commercialize agent japan portola retain rights andexanet alfa outside japan responsible manufacturing supply addition transaction bms provide notice termination california institute biomedical research pertain research collaboration agreement development antifibrotic preclinical compound dual therapeutic llc pertain research collaboration agreement development anticancer preclinical compound result operation regional revenue composition change revenue follow year end december total revenue analysis change analysis change total foreign total foreign dollar million change exchangeb change exchangeb united states europe rest world othera total revenue include royalty alliancerelate revenue product sell regional commercial organization foreign exchange impact derive apply prior period average currency rate current period sale increase revenue result high demand opdivo eliquis daklinza partially offset year impact expirationtransfer commercialization right abilify erbitux average net selling price increase approximately chargeback rebate discount refer product revenue commentary additional information increase revenue result launch opdivo daklinza high demand eliquis sprycel partially offset partial year impact expirationtransfer commercialization right abilify erbitux average net selling price increase approximately charge back rebate discount increase europe revenue result high demand opdivo eliquis partially offset low demand yervoy europe revenue include recognition approximately million previously defer daklinza revenue france decrease europe revenue result unfavorable foreign exchange expiration commercialization right abilify june partially offset launch daklinza certain country quarter high demand eliquis europe revenue impact recognition previously defer daklinza revenue france decrease rest world revenue result increased competition hepatitis franchise japan unfavorable foreign exchange primarily latin america partially offset high demand opdivo eliquis increase rest world revenue result launch daklinza sunvepra dual regimen japan quarter high demand eliquis partially offset unfavorable foreign exchange primarily japan decrease revenue result expiration certain supply arrangement decrease revenue result expirationtransfer certain licensing royalty right refer item financial statementsnote alliance discussion alliance single country outside contribute total revenue japan contribute total revenue grosstonet adjustment recognize revenue net grosstonet adjustment describe critical accounting policy share certain abilify atripla revenue reflect net grosstonet adjustment alliance revenue present grosstonet adjustment table share abilify atripla grosstonet adjustment approximately million billion billion grosstonet adjustment decrease expiration commercialization right abilify april activity end reserve balance significant category grosstonet adjustment follow rebate chargeback medicaid medicare return discount dollar million cash discount rebate adjustment total balance january provision relate sale current period prior period return payment foreign currency translation balance december provision relate sale current period prior period return payment foreign currency translation balance december reconciliation gross product sale net product sale significant category grosstonet adjustment follow exclude alliance revenues abilify atripla year end december change dollar million gross product sale grosstonet adjustment chargeback cash discount medicaid medicare rebate rebate return discount adjustment total grosstonet adjustment net product sale change grosstonet adjustment primarily function change sale volume payer channel mix contractual legislative discount rebate grosstonet adjustment increase high rate gross product sale primarily increase mix versus international gross product sale adjustment high chargeback cash discount increase period primarily high eliquis opdivo product sale medicaid medicare rebates increase period primarily high eliquis product sale rebate return discount adjustment increase primarily high worldwide sale eliquis opdivo increase high sale eliquis additional rebate daklinza approximately million amount previously defer france product revenue year end december change dollar million oncology empliciti elotuzumab nonus erbitux cetuximab nonus opdivo nivolumab nonus sprycel dasatinib nonus yervoy ipilimumab nonus cardiovascular eliquis apixaban nonus immunoscience orencia abatacept nonus virology baraclude entecavir nonus hepatitis franchise daclatasvir asunaprevir nonus reyataz atazanavir sulfate franchise nonus sustiva efavirenz franchise nonus neuroscience abilify aripiprazole nonus mature product nonus change excess empliciti humanize monoclonal antibody treatment multiple myeloma empliciti launch december japan september erbitux monoclonal antibody treatment certain type metastatic colorectal cancer scchn bms transfer right erbitux north america lilly october refer item financial statementsnote alliance discussion opdivo fully human monoclonal antibody bind nkt cell approve continue investigate anticancer treatment refer significant product pipeline approval discussion opdivo approval international revenue increase period high demand result rapid commercial acceptance indication include melanoma head neck lung kidney blood cancer expect competition increase sprycel oral inhibitor multiple tyrosine kinase indicate firstline treatment adult philadelphia chromosomepositive chronic myeloid leukemia chronic phase treatment adult chronic accelerate myeloid lymphoid blast phase chronic myeloid leukemia resistance intolerance prior therapy include gleevec imatinib meslylate revenue increase period high average net selling price demand international revenue increase high demand international revenue decrease unfavorable foreign exchange partially offset high demand experience decline european revenue second half unfavorable epo board appeal decision yervoy monoclonal antibody treatment patient unresectable metastatic melanoma revenue increase high demand result approval adjuvant treatment opdivoyervoy regimen patient metastatic melanoma revenue decrease low demand result introduction product treat patient melanoma include opdivo international revenue decrease low demand result introduction product treat patient melanoma include opdivo international revenue decrease unfavorable foreign exchange eliquis oral factor inhibitor target stroke prevention adult patient nonvalvular atrial fibrillation prevention treatment venous thromboembolic disorder international revenue increase period high demand result increase commercial acceptance novel oral anticoagulant market share gain orencia fusion protein indicate adult patient moderate severe active indicate reduce sign symptom certain pediatric patient moderately severely active polyarticular juvenile idiopathic arthritis revenue increase period high average net selling price demand international revenue increase period high demand partially offset unfavorable foreign exchange baraclude oral antiviral agent treatment chronic hepatitis revenue continue decrease period loss exclusivity september international revenue decrease follow loss exclusivity south korea october international revenue decrease unfavorable foreign exchange partially offset high demand certain country hepatitis franchise daklinza nsa replication complex inhibitor sunvepra protease inhibitor daklinza launch july international revenue decrease low demand result increase competition primarily japan international revenue include recognition approximately million previously defer daklinza revenue france international revenue increase high demand follow launch certain country japan quarter subsequent approval international market international revenue expect significantly decline low demand result increase competition reyataz franchise include reyataz protease inhibitor treatment hiv evotaz atazanavir cobicistat combination therapy contain reyataz tybost revenue continue decrease period low demand result increase competition partially offset high average net selling price loss exclusivity reyataz expect december experience high decline revenue future period generic competition international revenue continue decrease period low demand result increase competition unfavorable foreign exchange sustiva franchise nonnucleoside reverse transcriptase inhibitor treatment hiv include sustiva antiretroviral drug bulk efavirenz include combination therapy atripla revenue continue decrease period low demand result increase competition partially offset high average net selling price loss exclusivity sustiva expect december result termination joint venture agreement gilead reduce revenue international revenue continue decrease period sustiva loss exclusivity europe november abilify antipsychotic agent treatment schizophrenia bipolar mania disorder major depressive disorder commercialization right abilify expire april international revenue decrease period follow expiration commercialization rights june otsuka principal end customer sale certain market mature product include product include lose exclusivity major market diabetes alliance product otc brand royalty revenue revenue decrease favorable impact sale return reserve reduction plavix million revenue decrease primarily diabetes business divestiture february international revenue decrease expiration certain supply arrangement low sale divestiture certain mature product increase competition otc product unfavorable foreign exchange international revenue decrease expirationtransfer certain licensing royalty right diabetes business divestiture unfavorable foreign exchange continue generic erosion estimate endus demand pursuant sec consent order describe sec consent order monitor level inventory hand wholesaler distribution channel outside direct customer distribution channel obligate disclose product level inventory excess month hand expect demand subject minimis exception estimate level inventory distribution channel excess month hand follow product material result operation date indicate product estimate level inventory distribution channel excess month hand december international product estimate level inventory distribution channel excess month hand september dafalgan analgesic product sell principally europe month inventory hand internationally direct customer compare month inventory hand june level inventory hand primarily order pattern pharmacist france efferalgan analgesic product sell principally europe month inventory hand internationally direct customer compare month inventory hand june level inventory hand primarily order pattern pharmacist france fervex cold flu product month inventory hand direct customer compare month inventory hand june level inventory hand primarily france support product seasonality perfalgan analgesic product month inventory hand internationally direct customer compare month inventory hand june level inventory hand primarily gulf country saudi arabia extend delivery lead time generally determine month hand estimate inventory level product hand outmovement provide large wholesaler account approximately total gross sale product factor influence estimate include generic competition seasonality product wholesaler purchase light increase wholesaler list price new product launch new warehouse opening wholesaler new customer stocking wholesaler addition estimate calculate thirdparty datum impact recordkeeping process nonus business significantly direct customer information available direct customer product level inventory correspond movement information reliability thirdparty demand information vary widely limit direct customer sale channel inventory report influence demand information exist available develop variety methodology estimate datum include historical sale direct customer thirdparty market research datum relate prescription trend endus demand give difficulty inherent estimate thirdparty demand information evaluate methodology estimate direct customer product level inventory calculate month hand ongoing basis change necessary factor affect estimate include generic competition seasonality product price increase new product launch new warehouse opening direct customer new customer stocking direct customer expect direct customer purchase governmental bidding situation information require estimate month hand direct customer distribution channel nonus business year end december available prior file annual report disclose product level inventory excess month hand expect demand subject minimis exception quarterly report form expense change dollar million cost product sell marketing sell administrative research development incomeexpense total expense change excess cost product sell cost product sell include material internal labor overhead cost own manufacturing site thirdparty processing cost supply chain cost manage global manufacturing supply organization cost product sell include royalty profit sharing attribute license product alliance foreign currency hedge settlement gain loss amortization acquire develop technology cost business combination regulatory approval milestone cost product sell typically vary period result product mix volume particularly result royalty profit sharing expense connection alliance change foreign currency price inflation cost attribute rationalization manufacturing site result accelerated depreciation impairment charge strand cost cost product sell increase primarily high eliquis profit share million low foreign currency hedge settlement gain high puerto rico excise tax cost product sell remain relatively flat high eliquis profit sharing million offset favorable foreign exchange marketing sell administrative marketing selling administrative expense include salary benefit cost thirdparty professional marketing fee outsource fee shipping handling cost advertising product promotion expense attribute product manufacturing cost research development expense expense manage regional commercialization organization global enable function finance legal information technology human resource certain expense share alliance partner base contractual agreement expense typically vary period new product launch promotional activity marketing sell administrative expense increase high advertising promotion additional salesrelated activity support opdivo partially offset low spend virology product favorable foreign exchange marketing selling administrative expense remain relatively flat increase salesrelated activity support eliquis opdivo hepatitis franchise offset favorable foreign exchange million additional expense relate brand prescription drug fee result change irs guideline research development research development activity include discovery research preclinical clinical development drug formulation clinical trial medical support market product expense include salary benefit cost thirdparty grant fee pay clinical research organization supply upfront contingent milestone payment license asset acquisition investigational compound iprd impairment charge proportionate allocation enterprisewide cost allocation include facility information technology employee stock compensation cost appropriate cost certain expense share alliance partner base contractual agreement expense typically vary period number reason include time license asset acquisition charge iprd impairment charge research development expense decrease low license asset acquisition charge partially offset acceleration expansion opdivo development program capabilitie low iprd impairment charge research development expense increase high license asset acquisition charge acceleration expansion opdivo development program capability partially offset low iprd impairment charge favorable foreign exchange license asset acquisition charge million billion million include million padlock nitto denko flexus cormorant billion flexus cardioxyl prime million ipierian million milestone pay shareowner flexus commencement phase clinical trial iprd impairment charge million million million include million lpa antagonist million peginterferon lambda accelerate depreciation million million result expect exit certain site accelerate depreciation result reduction estimate useful life relate asset site date expect approximate million refer item financial statementsnote alliance note acquisition divestiture note goodwill intangible asset acquisition licensing arrangement nongaap financial measure specify item information incomeexpense income increase billion high divestiture gain royalty license income less extent low litigation settlement pension debt redemption charge expense decrease million low pension charge partially offset low divestiture gain divestiture gain million million million include certain otc product investigational hiv medicine business mount vernon indiana manufacturing facility erbitux ixempra certain mature otc product business diabete business royalty license income million million million include contingent consideration erbitux diabetes business divestiture include transfer certain future royalty right pertain amylin product sale pension charge million million million include additional pension charge million follow purchase group annuity contract prudential insurance company america provision restructure million million million october company announce evolution operating model drive company continue success near longterm focus investment commercial opportunity key brand market competitive agile organization accelerate pipeline streamline operation realign manufacturing capability broaden biologic capability reflect current future portfolio new operating model enable company deliver strategic financial operational flexibility necessary invest high priority company restructuring charge approximately million expect incur action addition accelerate depreciation impact discuss refer item financial statementsnote acquisition divestiture note incomeexpense note restructuring note pension postretirement benefit plan information income taxis dollar million earning income taxis provision income taxis effective tax rate historically effective income tax rate low statutory rate decision indefinitely reinvest earning certain manufacturing operation low tax jurisdiction switzerland ireland puerto rico bms operate favorable tax grant puerto rico schedule expire prior tax impact attribute charge divestiture transaction specify item include additional transfer pricing reserve increase effective tax rate reduce effective tax rate tax benefit attribute charge padlock flexus cormorant flexus cardioxyl ipierian lower nondeductible goodwill allocate business divestiture high valuation allowance attribute capital loss carryforward release impact effective tax rate minimal income taxis attribute diabetes business divestiture gain capital loss deduction sale amylin share tax basis difference result primarily allocate goodwill amylin defer taxis unfavorable earning mix high low tax jurisdiction high foreign tax credit result puerto rico excise tax period impact effective tax rate refer item financial statementsnote income taxis information comprehensive tax reform continues discuss propose include item change corporate tax rate border adjustment tax change tax foreign earning currently uncertain change enact effective date comprehensive tax reform occur financial condition result operation cash flow significantly impact unable determine potential impact time nongaap financial measure nongaap financial measure include nongaap earning relate eps information adjust exclude certain cost expense gain loss specify item evaluate individual basis item adjust consider quantitative qualitative aspect typically follow characteristic highly variable difficult project unusual nature significant result particular period indicative future operating result similar charge gain recognize prior period likely reoccur future period include restructuring cost accelerate depreciation impairment property plant equipment intangible asset charge connection acquisition license party intellectual property right divestiture gain loss pension legal contractual settlement charge debt redemption gain loss item defer current income taxis attribute item adjust consider individual impact overall tax expense deductibility jurisdictional tax rate nongaap information intend portray result baseline performance supplement enhance management analyst investor overall understand underlying financial performance facilitate comparison current past future period example nongaap earning ep information indication baseline performance item consider reflective ongoing result addition information primary indicator use basis evaluate performance allocate resource set incentive compensation target planning forecast future period information intend consider isolation substitute net earning dilute eps prepared accordance gaap specify item follow year end december dollar million cost product solda additional year brand prescription drug fee process standardization implementation cost marketing sell administrative license asset acquisition charge iprd impairment accelerate depreciation research development provision restructure litigation settlement divestiture gain royalty license income pension charge intangible asset impairment write option adjustment loss debt redemption otherb incomeexpense increase pretax income income taxis item specify tax chargec income taxis increase net earning specify item cost product sell accelerate depreciation asset impairment shutdown cost include million additional year brand prescription drug fee specify tax charge relate transfer pricing matter reconciliations gaap nongaap follow year end december dollar million share datum net earning attributable bms diluted eps calculation gaap specify item net earning attributable bms diluted eps calculation nongaap average common share outstanding dilute diluted eps attributable bms gaap dilute eps attributable specify item dilute eps attributable bms nongaap financial position liquidity capital resource net cash position follow dollar million cash cash equivalent marketable security current marketable security noncurrent total cash cash equivalent marketable security shortterm borrowing current portion longterm debt longterm debt net cash position cash cash equivalent marketable security hold approximately billion december remain billion hold primarily lowtax jurisdiction attributable earning expected indefinitely reinveste offshore cash repatriation subject restriction certain jurisdiction subject withholding additional income taxis believe exist cash cash equivalent marketable security cash generate operation issuance commercial paper sufficient satisfy normal cash requirement year include dividend capital expenditure milestone payment work capital maturity longterm debt management continuously evaluate company capital structure ensure company finance efficiently result repurchase common stock debt security termination interest rate swap contract prior maturity issuance debt security example issue senior unsecured note register public offering generating proceed billion redeemedrepurchase certain note nearly billion refer item financial statementsnote financial instrument fair value measurement detail companys common stock repurchase capacity increase billion october company enter asr agreement repurchase approximately billion common stock february refer item financial statementsnote equity detail dividend payment billion billion dividend decision quarterly basis board director capital expenditure approximately billion million million expect approximately billion million high spending expect result expand biologic manufacturing capability facilityrelate activity example construct new largescale biologic manufacturing facility ireland produce multiple therapy grow biologic portfolio complete marketable security portfolio subject change fair value result interest rate fluctuation market factor impact result operation investment policy place limit investment time maturity investment institution policy require investment enter corporate financial institution meet high credit quality standard refer item financial statement note financial instrument fair value measurement detail currently separate billion revolving credit facility syndicate lender facility provide customary term condition financial covenant extend october july facility extendable annually year anniversary date consent lender borrowing outstanding revolve credit facility december additional regulation pass future reduce result operation operate cash flow liquidity financial flexibility continue monitor potential impact economic condition certain european country relate impact prescription trend pricing discount creditworthiness customer believe economic condition material impact liquidity cash flow financial flexibility vote depart june similar company industry certain regulatory trade labor aspect business likely affect time currently believe matter relate financial effect material impact consolidate result operation financial position liquidity sale represent total revenue credit rating bms longterm shortterm credit rating assign moody investor service prime respectively negative longterm credit outlook bms longterm shortterm credit rating assign standard poor respectively stable longterm credit outlook bms longterm shortterm credit rating assign fitch respectively stable longterm credit outlook longterm rating reflect agency opinion low default risk somewhat susceptible adverse effect change circumstance economic condition shortterm rating reflect agency opinion good extremely strong capacity timely repayment credit rating downgrade affect interest rate debt incur fair market value exist debt ability access capital market generally cash flow follow discussion cash flow activity dollar million cash flow provide byused operating activity invest activity financing activity operate activity cash flow operating activity represent cash receipt disbursement activity invest financing activity operate cash flow derive adjust net earning noncontrolle interest noncash operating item gain loss attribute invest financing activity change operate asset liability result time difference receipt payment cash transaction recognize result operation result change cash operating activity reflect time cash collection customer alliance partner payment supplier alliance partner employee customer discount rebate tax payment ordinary course business example annual employee bonus typically pay quarter subsequent year addition cash collection continue impact long payment term certain biologic product primarily new oncology product include opdivo yervoy empliciti day day long payment term closely align insurance reimbursement time physician cancer center follow administration patient billion increase cash provide operating activity primarily attributable high operating cash flow attribute increase sale time cash collection payment ordinary course business include winddown abilify alliance lower upfront milestone payment alliance license arrangement approximately million partially offset high income tax payment approximately billion billion decrease cash provide operating activity primarily attributable timing payment alliance partner approximately million particularly active product ingredient supply medicaid rebate abilify high upfront payment new alliance licensing agreement approximately million timing customer collection result primarily high net product sale include extended payment term certain new product factor approximately million partially offset time cash collection payment ordinary course business include item change inventory level particularly relate abilify investing activity cash requirement invest activity include cash acquisition manufacturing facilityrelate capital expenditure purchase marketable security maturity great day reduce proceed business divestiture include royalty sale maturity marketable security billion decrease cash investing activity primarily attributable high net redemption marketable security approximately billion reinvested cash equivalent manage credit interest rate risk low asset acquisition payment approximately million asset acquisition include cormorant padlock flexus cardioxyl high business divestiture proceed approximately million include royalty contingent consideration receive subsequent divestiture divestiture include certain otc product investigational hiv business mount vernon indiana manufacturing facility ixempra mature otc product business partially offset high capital expenditure approximately million billion decrease cash provide investing activity primarily attributable low business divestiture proceed billion divestiture include mount vernon indiana manufacturing facility ixempra mature otc product business diabete business high asset acquisition payment approximately million asset acquisition include flexus cardioxyl ipierian high capital expenditure approximately million partially offset low net purchase marketable security billion financing activity cash requirement financing activity include cash pay dividend repurchase common stock repay longterm debt borrowing reduce proceed exercise stock option issuance longterm debt borrowing million decrease cash financing activity primarily attributable low longterm net debt repayment approximately million high net shortterm borrowing approximately million consist primarily change bank overdraft partially offset repurchase common stock approximately million million increase cash financing activity primarily attributable low net shortterm borrowing approximately million consist primarily change bank overdrafts contractual obligation payment period contractual obligation december follow obligation expire period dollar million total later year shortterm borrowing longterm debt interest longterm debta operating lease purchase obligation uncertain tax positionsb longterm liabilitiesc total include estimate future interest payment periodic cash settlement derivative include shortterm uncertain tax benefit uncertainty timing resolution include pension liability addition commit aggregate billion potential future research development milestone payment party license asset acquisition development program include earlystage milestone billion milestone achieve phase iii clinical trial late stage milestone billion milestone achieve post phase iii clinical trial payment generally payable achievement certain developmental regulatory milestone specific timing predict agreement provide salesbased milestone aggregate billion obligate pay alliance partner achievement certain sale level addition royalty certain manufacturing development commercialization obligation connection alliance arrangement practicable estimate obligation refer item financial statementsnote alliance information alliance discussion contractual obligation refer item financial statementsnote income taxis note financial instrument fair value measurementsand note pension postretirement postemployment liabilitie sec consent order fcpa settlement previously disclose august enter final settlement sec concluding investigation concern certain wholesaler inventory accounting matter settlement reach consent copy attach exhibit quarterly report form period end september term consent agree subject certain define exception limit sale product sell direct customer include wholesaler distributor hospital retail outlet pharmacie government purchaser base expect demand amount exceed approximately month inventory hand make timely public disclosure change practice agree consent certain measure implement include establish formal review certification process annual quarterly report file sec establish business risk disclosure group retain outside consultant comprehensively study help reengineer accounting financial reporting process publicly disclose sale incentive offer direct customer purpose induce purchase product excess expect demand ensure budget process give appropriate weight input come adequately document process establish companywide policy limit sale direct customer purpose comply consent policy include adoption procedure monitor limit sale direct customer accordance term consent procedure include governance process escalate appropriate management level potential question concern compliance policy timely resolution question concern addition compliance policy monitor regular basis maintain ima pharmaceutical wholesaler account nearly gross revenue current term ima wholesaler customer provide weekly information respect month hand productlevel inventory outmovement product large wholesaler currently account approximately gross revenue inventory information receive wholesaler internal information estimate month hand product level inventory wholesaler estimate month hand product inventory level businesss wholesaler customer large wholesaler extrapolate month hand calculate large wholesaler contrast nonus business significantly direct customer limit information direct customer product level inventory correspond outmovement information reliability thirdparty demand information available vary widely accordingly rely variety method estimate month hand product level inventory business unit believe abovedescribe procedure provide reasonable basis ensure compliance consent addition previously disclose october company reach civil settlement sec allege fcpa violation company agree pay approximately million disgorgement penalty interest settlement company agree twoyear selfmonitore period report government maintain procedure ensure compliance recently issue accounting standard recently issue accounting standard refer item financial statementsnote accounting policiesrecently issue accounting standard critical accounting policy preparation financial statement require use estimate assumption affect report amount asset liability report amount revenue expense critical accounting policy significantly impact financial condition result operation require difficult subjective complex judgment result need estimate effect matter inherently uncertain uncertainty actual result vary estimate revenue recognition accounting policy revenue recognition substantial impact report result rely certain estimate revenue recognize persuasive evidence arrangement exist sale price fix determinable collectability reasonably assure title substantially risk reward ownership transfer generally shipment certain market occur delivery product customer defer approximately million invoice daklinza early access program france portion recognize revenue final pricing obtain revenue reduce grosstonet sale adjustment discuss involve significant estimate judgment consider legal interpretation applicable law regulation historical experience payer channel mix medicare medicaid current contract price applicable program unbilled claim processing time lag inventory level distribution channel estimate assess period adjust require revise information actual experience alliance arrangement involve delivery element undelivered element evaluate qualify separate unit accounting consideration fix determinable allocate undelivered element recognize related good service deliver limited consideration contingent future deliverable consideration associate contingent milestone royalty allocate underlie element amount determined payable bms grosstonet adjustment follow category grosstonet adjustment involve significant estimate judgment information obtain external source refer total revenue discussion analysis significant category grosstonet sale adjustment chargeback cash discount business participate program government entity significant department defense department veteran affair party include cover entity drug pricing program pricing product extend wholesaler list price participate entity entity purchase product wholesaler low program price wholesaler charge difference acquisition cost low program price account receivable reduce estimate unprocessed chargeback claim attributable sale typically week time lag certain country cash discount offer incentive prompt payment generally approximate sale price account receivable reduce estimate unprocessed cash discount typically month time lag medicaid medicare rebate business participate state government medicaid program qualify federal state government program require discount rebate participate state local government entity discount rebate provide program include medicaid rebate accrual medicaid rebate extend drug manage medicaid plan estimate unpaid unbilled rebate present liability rebate discount offer manage healthcare organization manage prescription drug program medicare advantage prescription drug plan cover medicare drug benefit pay point service discount center medicare medicaid services medicare beneficiarie coverage gap donut hole estimate unpaid unbilled rebate discount present liability rebate return discount adjustment grosstonet sale adjustment include sale return program base applicable law regulation individual nonus country rebate offer manage healthcare organization less extent nonus program include different pricing scheme cost cap volume discount outcomebase pricing scheme pricing clawback base sale individual company aggregation company participate specific market estimate unpaid unbilled rebate discount present liability estimate return establish product determine consider historical experience factor include level inventory distribution channel estimate shelf life product recall product discontinuance price change competitive product introduction generic product introduction competitive new product low demand follow loss exclusivity estimate product return present liability estimate return new product determine consider historical sale return experience similar product product line similar therapeutic area andor similar distribution model defer recognition revenue right return expire sufficient historical experience estimate sale return develop limited circumstance insufficient historical experience product similar therapeutic area distribution method characteristic available typically occur new product extension exist line product historical experience product similar therapeutic category lack estimate level inventory distribution channel project demand consider estimate sale return new product use information external source information external source estimate grosstonet adjustment estimate inventory wholesaler base project prescription demandbase sale product historical inventory experience analysis thirdparty information include write oral information obtain certain wholesaler respect inventory level sellthrough customer thirdparty market research datum internal information inventory information receive wholesaler product recordkeeping process exclude inventory hold intermediary sell retailer hospital continue practice combine retail mail prescription volume retailequivalent basis use methodology internal demand forecast use information external source identify prescription trend patient demand average selling price estimate subject inherent limitation estimate rely thirdparty information certain thirdparty information form estimate reflect limitation include lags date thirdparty information generate date receive thirdparty information retirement benefit account pension postretirement benefit plan require actuarial valuation base significant assumption discount rate expect longterm rate return plan asset consultation actuary significant assumption salary growth retirement turnover healthcare trend mortality rate evaluate select base expectation actual experience remeasurement date pension expense vary range outcome material effect report earning project benefit obligation future cash fund actual result give year differ estimate economic factor yield high quality corporate bond coincide cash flow plan estimate payout determine discount rate citi pension discount curve plan present value benefit obligation december pension plan determine discount rate assume discount rate determine pension plan project benefit obligation december reduce additional project benefit obligation increase approximately million expect longterm rate return plan asset estimate consider expect return individual asset class input external advisor consider longterm historical return include actual performance compare benchmark similar investment plan pension expense determine expect longterm rate return plan asset expect longterm rate return plan asset determine plan pension expense reduce expense increase million detailed discussion retirement benefit refer item financial statementsnote pension postretirement postemployment liabilitie business combination divestiture goodwill intangible asset acquire business combination licensing transaction billion represent total asset december accounting transaction business combination divestiture significantly different asset acquisition divestiture example acquire iprd capitalize business combination expense asset acquisition fair value contingent consideration goodwill recognize business combination transaction likewise portion report unit constitute business divest goodwill associate business include carry value business determine gain loss derecognition goodwill occur asset disposition result important determine business asset group asset acquire divest business define asc business combination integrate set input process capable generate output ability provide return investor owner typical input include longlive asset include intangible asset right use longlived asset intellectual property ability obtain access require resource typical process include strategic operational resource management process typically document evident organized workforce consider factor determine business acquire divest compound development phase commercial product involve example evaluate acquisition cormorant padlock cardioxyl flexus ipierian conclude significant process transfer transaction account asset acquisition result amount allocate lead investigational compound expense capitalize addition contingent consideration potential development regulatory approval sale base milestone salesbase royalty include purchase price refer item financial statementsnote acquisition divestiture discussion acquisition similarly evaluate divestiture investigational hiv medicine business business comprise alliance reckitt erbitux ixempra business comprise alliance medicine company valeant pharmaceuticals international inc diabetes business astrazeneca conclude necessary input process transfer consequently transaction account sale business result allocation goodwill million million million carrying value business determine gain sale contingent proceed related divestiture recognize realize valuation process require certain multiple element arrangement include determination judgmental complex matter discuss example bms purchase warrant give bms exclusive right acquire promedior require determination well estimate selling price separate element identify transaction warrant clinical development service similarly divestiture diabete business astrazeneca require determination well estimate selling price element include business supply development agreement include appropriate markup estimate fair value manufacture facility refer item financial statementsnote alliance discussion transaction impairment intangible asset include iprd intangible asset billion december include license million million allocate unapproved product develop technology right million capitalize software million iprd million intangible asset assess impairment current fact circumstance warrant review iprd assess annually intangible asset highly vulnerable impairment charge particularly newly acquire asset recently launch product iprd asset initially measure fair value reduction expectation valuation potentially lead impairment common potential risk leading impairment include competition early expect loss exclusivity pricing pressure adverse regulatory change clinical trial result delay failure obtain regulatory approval additional development cost inability achieve expect synergy high operating cost change tax law macroeconomic change complexity estimate fair value intangible asset connection impairment test similar initial valuation consider high risk nature research development industry success rate bring developmental compound market iprd impairment charge likely occur future period recognize million charge bms phase development treatment ipf million include million charge peginterferon lambda phase iii development treatment hcv discussion iprd impairment refer item financial statementsnote goodwill intangible asset property plant equipment property plant equipment test impairment current fact circumstance require review include likely asset dispose prior estimate remain useful life additionally longlive asset periodically review determine change fact circumstance result change estimate useful life asset possibly result acceleration depreciation circumstance exist estimate undiscounted future cash flow generate asset appropriate grouping asset compare carry value determine impairment exist low level identifiable cash flow asset determine impair loss measure base difference asset fair value carry value expectation future cash flow subject change base near longterm production volume margin generate asset potential alternative future use accelerate depreciation relate charge certain manufacturing facility million million million additional charge continue occur result company restructuring action announce fourth quarter contingency normal course business subject contingency legal proceeding claim arise business cover wide range matter include government investigation shareholder lawsuit product environmental liability contractual claim tax matter recognize accrual contingency probable liability incur loss reasonably estimate estimate subject uncertainty difficult predict actual result vary estimate discussion contingency refer item financial statementsnote accounting policiescontingencie note income taxis note legal proceeding contingency income taxis valuation allowance recognize reduce defer tax asset likely tax benefit realize assessment valuation allowance require require significant judgment include longrange forecast future taxable income evaluation tax planning initiative adjustment defer tax valuation allowance earning period assessment defer tax asset billion december net valuation allowance billion billion december net valuation allowance billion defer tax asset relate federal net operating loss carryforward million federal tax credit carryforward million recognize december net operating loss carryforward expire vary amount begin federal tax credit carryforward expire vary amount begin realization carryforward dependent generating sufficient domesticsource taxable income prior expiration million valuation allowance establish item december assured believe likely defer tax asset value realize taxis provide undistributed earning foreign subsidiary expect reinveste indefinitely offshore prior mead johnson splitoff follow transaction occur internal spinoff mead johnson share own conversion mead johnson class share class share iii conversion mead johnson company limited liability company transaction splitoff mead johnson exchange offer qualify taxexempt transaction internal revenue code base private letter ruling receive internal revenue service relate conversion mead johnson class share class share outside legal opinion certain assumption representation covenant mead johnson rely future conduct business matter affect tax treatment exchange example current tax law generally create presumption exchange taxable mead johnson shareholders engage transaction result great change stock ownership year period begin year exchange offer establish exchange offer plan series relate transaction effect change ownership internal spinoff exchange offer determine qualify tax exempt transaction transaction subject tax exchange taxable sale market value addition negative basis ela exist investment stock mead johnson prior transaction receive opinion outside legal counsel effect likely eliminate ela transaction taxable income respect ela tax law area complex possible internal spinoff exchange offer tax exempt internal revenue code irs assert additional taxable income period respect ela expose additional taxis occur base understand internal revenue code opinion outside legal counsel tax reserve million establish reduce gain disposal mead johnson include discontinued operation agree certain tax relate indemnity mead johnson set forth tax sharing agreement include certain taxis relate business prior completion ipo create restructure facilitate ipo mead johnson agree indemnify potential tax effect result breach certain representation discuss certain transaction relate acquisition mead johnson stock asset liability establish possible assessment tax authority result know tax exposure include limited transfer pricing matter tax credit deductibility certain expense liability represent reasonable provision taxis ultimately expect pay need adjusted time information know example additional reserve million establish certain transfer pricing matter relate period discussion income taxis refer item financial statementsnote accounting policiesincome taxis note income taxis product pipeline development program manage portfolio basis early discovery latestage development include balance earlystage latestage program support future growth late stage program phase iii development include investigational compound initial indication additional indication formulation market product spending program represent approximately annual expense year individual investigational compound market product represent expense year opdivo latestage development program potentially impact revenue earning year regulatory approval obtain product successfully commercialize follow development market product latestage pipeline product indication date development jmhlw manufacturing marketing approval treatment relapse refractory chl receive december alliance partner ono bms seattle genetics inc announce result phase iii study evaluate adcetris brentuximab december combination opdivo relapse refractory chl approval treatment adult patient relapse refractory chl asct treatment november chl brentuximab vedotin announce new result checkmate phase trial evaluate opdivo patient chl include october patient receive brentuximab vedotin andor autohsct june announce result checkmate phase trial evaluate opdivo patient chl fda approval treatment patient chl relapse progress autohsct posttransplantation brentuximab vedotin announce result ono phase iii trial evaluate opdivo patient unresectable advanced january recurrent gastric cancer refractory intolerant standard therapy november announcement gastric cancer state study meet primary endpoint ono alliance partner conduct trial bms alliance partner ono submit supplemental application opdivo treatment unresectable december advanced recurrent gastric cancer announce extended followup datum phase trial evaluate opdivo heavily pretreate april advanced melanoma patient melanoma fda expand use opdivo single agent include previously untreated braf mutation positive january advanced melanoma patient fda approval treatment patient previously treat locally advanced muc type bladder february cancer announce result checkmate phase trial evaluate opdivo platinumrefractory patient october muc muc announce ema validate company type variation application seeks extend current opdivo september indication include treatment locally advanced muc adult failure prior platinumcontaine therapy announce datum checkmate phase iii trial evaluate opdivo patient muc platinum june base therapy announce update result phase iii trial checkmate checkmate evaluate october opdivo previously treat metastatic nsclc patient present final primary analysis checkmate phase iii trial evaluate opdivo firstline october monotherapy patient advance nsclc tumor express pdl line result nsclc disclose august show checkmate meet primary endpoint superior pfs announce datum phase iii trial checkmate checkmate evaluate opdivo versus docetaxel previously treat metastatic nsclc april approval treatment previously treat patient metastatic nsq nsclc jmhlw manufacturing marketing approval treatment unresectable metastatic rcc receive august alliance partner ono rcc announce longterm result doserange study phase study phase june study evaluate opdivo patient previously treat advanced rcc april approval treatment previously treat patient advance rcc fda approval treatment patient scchn disease progression platinumbase november therapy announce new datum checkmate phase iii trial evaluate opdivo patient recurrent october metastatic scchn platinum therapy compare investigator choice therapy scchn ema validate japan bms alliance partner ono submit application opdivo patient july previously treat recurrent metastatic scchn announce datum checkmate phase iii trial evaluate opdivo patient recurrent april metastatic scchn platinum therapy compare investigator choice therapy january checkmate stop early dmc concluding study meet primary endpoint product indication date development announce datum checkmate phase trial evaluate opdivo combination yervoy colorectal cancer june patient previously treat metastatic colorectal cancer include msih announce result trial checkmate phase iii checkmate phase evaluating june opdivoyervoy combination regiman previously untreate advanced melanoma approval treatment unresectable metastatic melanoma regardless braf mutational status melanoma announce datum checkmate phase trial evaluate opdivoyervoy combination regiman april previously untreate advanced melanoma fda expand use treatment previously untreated unresectable metastatic melanoma regardless january opdivoyervoy braf mutational status announce additional result checkmate phase iii trial investigate combination schedule muc november opdivoyervoy patient locally advance muc previously treat platinumbase therapy announce update finding checkmate phase trial evaluate opdivo monotherapy nsclc december combination yervoy patient chemotherapynave advanced nsclc datum previously announce june announce update result checkmate phase trial evaluate opdivo yervoy combination rcc october regimen previously treat treatmentnave patient metastatic rcc announce update result checkmate phase iii trial evaluate opdivo monotherapy sclc december combination yervoy previously treat sclc patient jmhlw manufacturing marketing approval combination revlimid lenalidomide september dexamethasone treatment multiple myeloma empliciti multiple myeloma approval treatment multiple myeloma combination therapy revlimid dexamethasone patient receive prior therapy announce new datum phase iii trial evaluate yervoy stage iii melanoma patient yervoy melanoma october high risk recurrence follow complete surgical resection approval combination mtx treatment highly active progressive disease adult september patient previously treat mtx announce commercial launch orencia clickject autoinjector new selfadministered autoinjector orencia july adult moderate severe present finding observational study explore moderate severe patient response june treatment base baseline status biomarker poor prognosis anticcp jmhlw manufacturing marketing approval ximency combination tablet contain daclatasvir december asunaprevir beclabuvir treatment hcv genotype fda approval daklinza use sofosbuvir treatment chronic hcv genotype hepatitis february hcv additional patient population portfolio announce result complete alloral chronic hcv regimen daklinza combination february asunaprevir phase iii trial include chinese patient population approval daklinza use sofosbuvir treatment chronic hcv new patient january population approval reyataz oral powder indicate hivinfecte child month reyataz hiv june optimize reyataz capsule pediatric dose recommendation special note forwardlooke statement annual report include document incorporate reference write oral statement time time contain certain forwardlooking statement meaning section security act section securities exchange act identify forwardlooke statement fact use word expect anticipate estimate target project guidance intend plan believe word term similar meaning expression connection discussion future operate financial performance identify forwardlooke statement fact relate strictly historical current fact forwardlooke statement base current expectation involve inherent risk uncertainty include factor delay divert change cause actual outcome differ materially current expectation statement likely relate thing goal plan projection financial position result operation cash flow market position product development product approval sale effort expense performance result current anticipate product outcome contingency legal proceeding financial result base current expectation involve inherent risk uncertainty include internal external factor delay divert change year include important factor cautionary statement include annual report particularly item risk factor believe cause actual result differ materially forwardlooke statement believe prudent plan assumption assurance give goal plan set forth forwardlooke statement achieve reader caution place undue reliance statement speak date undertake obligation release publicly revision forwardlooke statement result new information future event item quantitative qualitative disclosure market risk expose market risk result change currency exchange rate interest rate certain derivative financial instrument available costeffective basis hedge underlie economic exposure financial instrument include derivative subject counterparty credit risk consider overall fair value measurement derivative financial instrument trading purpose foreign exchange risk significant amount revenue earning cash flow expose change foreign currency rate primary net foreign currency translation exposure euro japanese yen chinese renminbi foreign currency forward contract manage risk primarily arise certain intercompany purchase transaction designate foreign currency cash flow hedge appropriate addition expose foreign exchange transaction risk arise nonfunctional currency denominate asset liability earning denominate nonus dollar currency foreign currency forward contract offset exposure designate hedge estimate appreciation underlie currency hedge level dollar variable hold constant decrease fair value foreign exchange forward contract million december reduce earning remain life contract expose translation risk nonus dollardenominate net asset nonus dollar borrowing hedge foreign currency exposure net investment certain foreign affiliate designate hedge net investment effective portion foreign exchange gain loss hedge include foreign currency translation component accumulate comprehensive incomeloss net investment decrease equivalent value nonus debt borrowing change remeasurement basis debt subject recognition income change occur additional information refer item financial statementsnote financial instrument fair value measurement interest rate risk use fixedtofloate interest rate swap contract designate fair value hedge forward start interest rate swap contract designate cash flow hedge interest rate risk management strategy contract intend provide appropriate balance fix float rate debt forward start swap contract manage interest rate future debt issuance estimate increase basis point shortterm longterm interest rate decrease fair value interest rate swap contract million decrease basis point shortterm longterm interest rate decrease fair value forward start interest rate swap contract million reduce earning remain life contract estimate increase basis point longterm interest rate decrease fair value longterm debt million marketable security subject change fair value result interest rate fluctuation market factor policy inv institution meet high credit quality standard estimate increase basis point interest rate general decrease fair value debt investment portfolio approximately million credit risk material certain european governmentbacke entity high risk default greece portugal italy spain monitor economic factor include credit rating creditdefault swap rate debttogross domestic product ratio entity specific factor historically exposure limited factoring receivables credit exposure europe increase future reduction factor arrangement ongoe sovereign debt crisis monitor investment counterpartie objective minimize concentration credit risk investment policy establishe limit time maturity investment individual counterparty policy require investment enter corporate financial institution meet high credit quality standard use derivative instrument expose credit risk fair value derivative instrument contract positive expose credit risk counterparty fails perform fair value derivative instrument contract negative counterparty expose credit risk fail perform obligation collateral require party derivative asset liability position policy diversify derivative counterpartie mitigate overall risk counterparty default additional information refer item financial statementsnote financial instrument fair value measurement item financial statement supplementary datum bristolmyer squibb company consolidate statement earning dollar million share datum year end december earning net product sale alliance revenue total revenue cost product sell marketing sell administrative research development incomeexpense total expense earning income taxis provision income taxis net earning net earning attributable noncontrolle interest net earning attributable bms earning common share basic diluted cash dividend declare common share consolidate statement comprehensive income dollar millions year end december comprehensive income net earning comprehensive incomeloss net taxis reclassification earning derivative qualify cash flow hedge pension postretirement benefit availableforsale security foreign currency translation total comprehensive loss comprehensive income comprehensive income attributable noncontrolle interest comprehensive income attributable bms accompany note integral consolidated financial statement bristolmyers squibb company consolidated balance sheet dollar million share share datum december asset current asset cash cash equivalent marketable security receivables inventory prepaid expense total current asset property plant equipment goodwill intangible asset defer income taxis marketable security asset total asset liability current liability shortterm borrowing current portion longterm debt account payable accrue liability defer income income taxis payable total current liability defer income income taxis payable pension liability longterm debt total liability commitment contingency note equity bristolmyers squibb company shareholder equity prefer stock convertible series par value share authorize million share issue outstanding liquidation value share common stock par value share authorize billion share billion issue capital excess par value stock accumulate comprehensive loss retain earning cost treasury stock million common share million total bristolmyer squibb company shareholder equity noncontrolle interest total equity total liability equity accompany note integral consolidated financial statement bristolmyers squibb company consolidate statement cash flow dollar million year end december cash flow operating activity net earning adjustment reconcile net earning net cash provide operating activity depreciation amortization net defer income taxis stockbase compensation impairment charge pension settlement amortization divestiture gain royalty net asset acquisition charge adjustment change operate asset liability receivable inventory account payable deferred income income taxis payable net cash provide operating activity cash flow invest activity sale maturity marketable security purchase marketable security capital expenditure divestiture proceed acquisition payment net cash provide byused investing activity cash flow financing activity shortterm borrowing net issuance longterm debt repayment longterm debt interest rate swap contract termination issuance common stock repurchase common stock dividend net cash financing activity effect exchange rate cash cash equivalent increasedecrease cash cash equivalent cash cash equivalent begin year cash cash equivalent end year accompany note integral consolidated financial statement note accounting policy recently issue accounting standard basis consolidation consolidate financial statement prepare conformity gaap include account bristolmyer squibb company control majorityowned subsidiary certain variable interest entity intercompany balance transaction eliminate material subsequent event evaluate disclose report issuance date refer summary abbreviate term end term document alliance license arrangement assess determine term provide economic control entity require consolidation entity entity control mean majority voting interest refer variable interest entity consolidate bms power direct activity variable interest entity significantly impact economic performance obligation absorb loss right receive benefit potentially significant entity use estimate judgment preparation financial statement requires use management estimate judgment assumption significant assumption estimate determine fair value potential impairment intangible asset sale rebate return accrual legal contingency income taxis estimate selling price multiple element arrangement determine acquisition divestiture business asset pension postretirement benefit actual result differ estimate result reclassification certain prior period amount reclassify conform current period presentation reclassification provide concise financial statement presentation additional information disclose note material prior presentation current presentation consolidate statement include marketing sell administrative advertising product promotion earning expense asset heldforsale include prepay expense accrue expense accrue rebate return combine accrue liability consolidate balance sheet dividend payable pension postretirement postemployment liability combine pension liability liabilitie net earning attributable noncontrolle interest include adjustment consolidate statement divestiture gain royalty include adjustment divestiture gain royalty cash flow asset acquisition charge include adjustment asset acquisition charge revenue recognition revenue recognize persuasive evidence arrangement exist sale price fix determinable collectability reasonably assure title substantially risk reward ownership transfer generally time shipment include supply commercial product alliance partner principal end customer sale certain revenue nonus business recognize date receipt customer alliance revenue relate abilify atripla recognize product sell end customer alliance partner royalty recognize thirdparty sale reliably measurable collectability reasonably assure refer note alliance detail alliance revenue reduce time recognition expect sale return discount rebate sale allowance base historical experience update change fact circumstance include impact applicable healthcare legislation revenue defer historical experience product similar therapeutic category similar operational characteristic right return long exist sufficient historical experience estimate sale return develop income taxis provision income taxis include income taxis pay payable current year plus change defer taxis year defer taxis result difference financial tax basis asset liability adjust change tax rate tax law change enact valuation allowance recognize reduce defer tax asset likely tax benefit realize assessment valuation allowance require require significant judgment include longrange forecast future taxable income evaluation tax planning initiative adjustment defer tax valuation allowance earning period assessment tax benefit recognize uncertain tax position likely tax position sustain examination tax authority base technical merit position tax benefit recognize financial statement particular tax position base large benefit likely realize settlement cash cash equivalent cash cash equivalent include bank deposit time deposit commercial paper money market fund cash equivalent consist highly liquid investment original maturity month time purchase recognize cost approximate fair value marketable security investment company marketable security classify availableforsale date purchase report fair value fair value determine base observable market quote valuation model assessment counterparty credit worthiness credit default risk underlie security overall capital market liquidity investment own company account equity method accounting ability exercise significant influence maintain share net income loss equity investment include incomeexpense equity investment review impairment assess decline market value investment carry value temporary consider intent ability retain investment period time sufficient allow anticipated recovery market value duration extent market value cost investee financial condition inventory valuation inventory state low average cost market property plant equipment depreciation expenditure addition renewal improvement capitalize cost depreciation compute straightline method base estimate useful life relate asset range year building year machinery equipment fixture impairment longlive asset current fact circumstance periodically evaluate determine carry value depreciable asset hold recoverable circumstance exist estimate undiscounted future cash flow generate longlived asset appropriate grouping asset compare carry value determine impairment exist low level identifiable cash flow asset determine impair loss measure base difference asset fair value carry value estimate asset fair value base quote market price active market available quote market price available estimate fair value base valuation technique unobservable fair value input discount value estimate future cash flow capitalize software eligible cost obtain internal use software capitalize amortize estimate useful life software acquisition business acquire consolidate obtain control fair value asset acquire liability assume recognize date acquisition excess purchase price estimate fair value net asset acquire recognize goodwill business acquisition cost expense incur contingent consideration potential development regulatory approval salesbase milestone salesbase royalty include purchase price business combination exclude asset acquisition amount allocate lead investigational compound asset acquisition expense date acquisition goodwill acquire inprocess research development intangible asset fair value intangible asset typically determine income method utilize level fair value input market participant valuation assume global view consider potential jurisdiction indication base discount aftertax cash flow projection risk adjust estimate probability technical regulatory success iprd finitelive intangible asset include license develop technology right iprd project reach commercialization amortize straightline basis estimate useful life estimate useful life determine consider period asset expect contribute future cash flow goodwill tested annually impairment assess qualitative factor perform quantitative analysis determine likely fair value net asset carry amount example qualitative factor assess include share price financial performance compare budget longterm financial plan macroeconomic industry market condition substantial excess fair value carry value net asset annual impairment test perform prior year relevant factor assess individually aggregate iprd test impairment annual basis frequently event occur circumstance change indicate potential reduction fair value asset carry value carry value iprd determine exceed fair value impairment loss recognize difference finitelive intangible asset test impairment fact circumstance suggest carry value asset recoverable carrying value exceed project undiscounted pretax cash flow intangible asset impairment loss equal excess carrying value estimate fair value discount aftertax cash flow recognize restructure restructuring charge recognize result action streamline operation rationalize manufacture facility estimate impact restructuring plan include future termination benefit exit cost require judgment actual result vary estimate contingency loss contingency legal proceeding claim occur wide range matter include government investigation shareholder lawsuit product environmental liability contractual claim tax matter accrual recognize probable liability incur loss reasonably estimate gain contingency include contingent proceed related divestiture recognize realize legal fee expense incurred shipping handle cost shipping handling cost include marketing sell administrative expense million million million advertising product promotion cost advertising product promotion cost include marketing sell administrative expense million million million advertising product promotion cost expense incur foreign currency translation foreign subsidiary earning translate dollar average exchange rate net asset foreign subsidiary translate dollar current exchange rate dollar effect arise translate net asset subsidiary change rate recognize oci research development research development cost expense incur clinical study cost accrue service period specify contract adjust necessary base ongoing review level effort cost actually incur strategic alliance party provide licensing right develop manufacture market andor sell pharmaceutical product right own party research development recognize net reimbursement connection alliance agreement upfront contingent milestone payment asset acquisition investigational compound include research development expense cash flow upfront contingent milestone payment license investigational compound include operating activity asset business acquisition include investing activity divestiture proceed include investing activity royalty consideration receive subsequent relate sale asset business adjustment reflect operating activity include divestiture gain loss relate royalty research development asset acquisition charge gain loss debt redemption change fair value write option liability recently issue accounting standard fasb issue new accounting standard relate revenue recognition require entity recognize revenue expect entitle transfer promise good service customer new standard subsequent amendment issued replace exist revenue recognition standard gaap effective january step model utilize achieve core principle identify customer contract identify contract performance obligation determine transaction price allocate transaction price performance obligation recognize revenue performance obligation satisfy new standard apply retrospectively prior reporting period present retrospectively cumulative effect change recognize date initial application retain earning disclosure nature time uncertainty revenue cash flow customer contract require company assessment new standard impact substantially complete base current contract currently believe timing recognize revenue typical net product sale customer significantly change new standard long require transaction price fix determinable certain variable consideration recognize prior occurrence resolution contingent event subject revenue reversal constraint result certain revenue previously defer current standard transaction price fix determinable early access program account variable consideration recognize early provide term sufficient reliably estimate ultimate price expect realize addition future royalty relate certain alliance arrangement sanofi japan erbitux arrangement disclose note alliance estimate recognize prior party sale occur provide probable estimate amount reverse future time royalty salesbase milestone form contingent consideration result divestiture business diabete north american erbitux business disclose note alliance royalty salesbase royalty licensing arrangement expect change new standard guidance pertaining separation licensing right relate fee recognition expected significantly change timing recognize revenue exist alliance arrangement currently generate revenue company currently anticipates adopt new standard modify retrospective basis cumulative effect change reflect retain earning january restate prior period result certain future royalty discuss estimate present cumulative effect accounting change exclude result operation begin subsequent significant revision estimate amount variable consideration pertain similar arrangement enter subsequent adoption new standard need estimate account comparable manner initial estimate reflect revenue assess subsequent reporting period significant change business process system control currently expect require january fasb issue amend guidance recognition measurement presentation disclosure financial instrument effective january early adoption permit new guidance require fair value adjustment equity security readily determinable fair value currently classify availableforsale report earning new guidance require qualitative impairment assessment equity investment readily determinable fair value charge earning impairment exist company expect amend standard material impact company result operation february fasb issue amend guidance lease accounting amend guidance require recognition rightofuse asset lease liability initially measure present value future lease payment lease term long month guidance effective begin early adoption permit modify retrospective approach company assessment amend standard complete minimal impact result operation expect undiscounted value lease obligation approximately million december consist primarily facility lease account operating lease initial rightofuse asset lease liability reflect adoption subject factor include actual lease portfolio early date initial application selection appropriate discount rate determine individual fix lease payment term include renewal period reasonably certain occur march fasb issue amend guidance sharebase payment transaction excess tax benefit deficiency recognize consolidated statement earning capital excess par value stock prospective basis policy election available account forfeiture occur cumulative effect change recognize adjustment retain earning date adoption excess tax benefit consolidated statement cash flow present operating activity prospective retrospective application cash payment tax authority connection share withhold statutory tax withholding requirement present financing activity retrospective application guidance effective beginning expect reduction income tax expense excess tax benefit expect material company continue current practice relate accounting forfeiture cash flow presentation change discuss increase net cash provide operating activity net cash financing activity million million june fasb issue amend guidance measurement credit loss financial instrument entity require use forwardlooke estimate loss model availableforsale debt security credit loss recognize allowance reduction amortize cost guidance effective begin early adoption permit modify retrospective approach company expect amend standard material impact company result operation october fasb issue amend guidance income tax accounting intraentity transfer asset inventory amend guidance require tax consequence transfer asset member consolidate group recognize period transfer take place exclude inventory guidance effective begin early adoption permit quarter modify retrospective approach company early adopt amend standard begin quarter result prepay receivables defer tax asset attribute internal intellectual property transfer approximately billion reduce cumulative effect accounting change retain earning long amortize component income taxis million year addition tax impact future internal transfer intellectual property include income tax expense transfer amortize subsequent period january fasb issue amend guidance revise definition business amendment provide initial screen substantially fair value gross asset acquire disposed concentrated single identifiable asset group similar identifiable asset asset represent business consider business input substantive process significantly contribute ability create output business output need organized workforce amendment narrow definition term output guidance effective begin early adoption permit prospectively company assess potential impact amend standard january fasb issue amend guidance simplifie recognition measurement goodwill impairment loss eliminate step quantitative impairment test result impairment charge require report unit carry exceed fair value allocate goodwill guidance effective prospective basis early adoption permit interim annual goodwill impairment test perform january company expect amend standard material impact company result operation note business segment information bms operate single segment engage discovery development licensing manufacturing marketing distribution sale innovative medicine help patient prevail disease global research development organization supply chain organization responsible discovery development manufacturing supply product regional commercial organization market distribute sell product business support global corporate staff function segment information consistent financial information regularly review chief executive officer purpose evaluate performance allocate resource set incentive compensation target planning forecast future period product sell principally wholesaler less extent directly distributor retailer hospital clinic government agency pharmacie gross revenue large pharmaceutical wholesaler percentage global gross revenue follow mckesson corporation amerisourcebergen corporation cardinal health inc select geographic area information follow revenue property plant equipment dollar millions united states europe rest worlda otherb total include japan represent total revenue respectively revenue include royalty alliancerelate revenue product sell regional commercial organization product revenue follow year end december dollar million oncology empliciti elotuzumab erbitux cetuximab opdivo nivolumab sprycel dasatinib yervoy ipilimumab cardiovascular eliquis apixaban immunoscience orencia abatacept virology baraclude entecavir hepatitis franchise reyataz atazanavir sulfate franchise sustiva efavirenz franchise neuroscience abilify aripiprazole mature product total revenue composition total revenue follow year end december dollar million net product sale alliance revenues revenues total revenue note alliance bms enter collaboration arrangement party development commercialization certain product arrangement unique nature party active participant operating activity collaboration expose significant risk reward depend commercial success activity bms inlicense intellectual property own party outlicense intellectual property party arrangement typically include research development manufacturing andor commercial activity cover single investigational compound commercial product multiple compound andor product life cycle stage right obligation party global limited geographic region refer collaboration alliance partner alliance partner product empliciti erbitux opdivo sprycel yervoy eliquis orencia sustiva atripla abilify product comprise diabetes alliance discuss certain mature brand include alliance arrangement payment alliance partner account present result operation consider specific nature payment underlie activity payment relate multiple alliance activity include transfer right separate individual unit account standalone value activity occur life arrangement situation arrangement consideration allocate activity right relative sell price basis multiple alliance activity right standalone value combine single unit account common activity bms alliance partner present result operation follow bms principal end customer sale product sale include net product sale bms alliance partner principal end customer sale bms contractual share thirdparty sale andor royalty income include alliance revenue sale commercial product consider bms ongoing major central operation refer revenue recognition include note accounting policy information recognition criterion amount payable bms alliance partner principal end customer sale supply commercial product include alliance revenue sale commercial product consider bms ongoing major central operation profit share royalty salesbase fee payable bms alliance partner include cost product sell incur cost reimbursement party recognize incur include cost product sell marketing sell administrative expense research development expense base underlying nature relate activity subject reimbursement upfront contingent development approval milestone payable bms alliance partner investigational compound commercial product defer amortize short contractual term period relate compound product expect contribute future cash flow amortization present consistent nature payment arrangement example amount receive investigational compound present incomeexpense activity perform time relate sale commercial product bmss ongoing major central operation amount receive commercial product present alliance revenue sale commercial product consider bmss ongoing major central operation astrazeneca alliance pertain amylin product discussion specific astrazeneca alliance disclosure upfront contingent approval milestone payable bms alliance partner commercial product capitalize amortize short contractual term period relate product expect contribute future cash flow amortization include cost product sell upfront contingent milestone payable bms alliance partner prior regulatory approval expense incur include research development expense royalty contingent consideration payable bms alliance partner relate divestiture business include income earn equity net income affiliate include incomeexpense payment bms alliance partner present cash flow operating activity describe select financial information pertain alliance follow include net product sale bms principal thirdparty customer sale product subject alliance expense summarize include amount attribute activity product alliance payment alliance partner relate amortization payment defer capitalize year end december dollar millions revenue alliance net product sale alliance revenue total revenue payment tofrom alliance partner cost product sell marketing sell administrative research development incomeexpense noncontrolle interest pretax select alliance balance sheet information december dollar million receivable alliance partner account payable alliance partner defer income alliancesa include unamortized upfront milestone licensing proceed revenue deferral attribute atripla undelivered element diabete business divestiture proceed amortization defer income primarily relate alliance million million million upfront payment new licensing alliance agreement include option license acquire related asset charge research development expense million million million specific information pertain significant alliance discuss include nature purpose significant right obligation party specific accounting policy election income statement classification amount attributable payment party pfizer bms pfizer party worldwide codevelopment cocommercialization agreement eliquis anticoagulant discover bms pfizer fund development cost depend study profit loss share equally global basis certain country pfizer commercialize eliquis pay bms compensation base percentage net sale enter agreement coexclusive license right product grant pfizer exchange upfront payment potential milestone payment party assume certain obligation actively participate alliance actively participate joint executive committee operating committee joint responsibility research development distribution sale marketing activity alliance resource infrastructure bms manufacture product alliance principal end customer product sale significant country europe canada australia china japan south korea bms transfer commercialization right pfizer certain small country order simplify operation transfer country bms supply product pfizer cost plus percentage net sale endcustomer company determine right transfer pfizer standalone value right sell separately bms party pfizer receive benefit deliver right fulfillment ongoing obligation bms alliance agreement include exclusive supply arrangement global alliance treat single unit accounting upfront proceed subsequent contingent milestone proceed amortize life relate product bms receive million nonrefundable upfront milestone licensing payment relate eliquis december amortization eliquis defer income include income eliquis commercial product commencement alliance summarize financial information relate alliance follow year end december dollar millions revenue pfizer alliance net product sale alliance revenue total revenue payment tofrom pfizer cost product sell profit sharing incomeexpense amortization defer income select alliance cash flow information defer income select alliance balance sheet information december dollar millions defer income gilead bms gilead joint venture canada europe develop commercialize atripla efavirenz emtricitabine tenofovir disoproxil fumarate combine sustiva product bms truvada emtricitabine tenofovir disoproxil fumarate product gilead joint venture consolidate gilead party actively participate joint executive committee operating committee direct oversight activity joint venture joint venture purchase sustiva truvada api bulk form party complete finishing atripla joint venture gilead sell distribute atripla principal end customer product sale party long coordinate joint promotional activity alliance revenue recognize atripla include bulk efavirenz component atripla base relative ratio average respective net selling price truvada sustiva alliance revenue defer related alliance receivable recognize combined product sell party customer europe follow loss exclusivity sustiva effective january percentage atripla net sale europe recognize bms equal difference average net selling price atripla truvada alliance continue europe party terminate arrangement patent expire allow market exclusivity atripla agreement terminate gilead launch generic version sustiva bms launch generic version truvada individual component loss exclusivity sustiva expect december event gilead terminate agreement loss exclusivity sustiva bms receive quarterly royalty payment month follow termination payment month follow termination equal atripla net sale multiply ratio difference average net selling price atripla truvada atripla average net selling price second year follow termination payment bms reduce respectively atripla net sale multiply price ratio describe bms continue supply sustiva cost plus markup joint venture threeyear period party elect terminate supply arrangement summarize financial information relate alliance follow year end december dollar million revenue gilead alliance alliance revenues equity net loss affiliate select alliance balance sheet information december dollar millions defer income otsuka bms worldwide commercialization agreement otsuka codevelop copromote abilify exclude certain asian country portion agreement expire april agreement expire country june nonus country exclusive right sell abilify agreement expire later april loss exclusivity country party actively participate joint executive governance operate committee otsuka responsible provide sale force effort effective january bms responsible certain operating expense annual limit bms purchase api otsuka complete manufacture product subsequent sale thirdparty customer certain country otsuka assume responsibility provide funding sale force effort effective april bms provide certain service include distribution customer management pharmacovigilance bms principal end customer product sale exclusive distributor exclusive right sell abilify otsuka principal end customer product sale alliance revenue include bmss share total net sale thirdparty customer territory assessment bms expect annual contractual share complete quarterly reporting period adjust base report abilify net sale year end bms annual contractual share alliance revenue recognize interim period quarter exceed amount contract bmss contractual share thirdparty net sale countrie alliance revenue recognize abilify ship risk reward ownership transfer thirdparty customer bms otsuka alliance sprycel japan oncology territory party copromote product february copromotion agreement otsuka terminate japan party actively participate governance committee bms control decision make bms responsible development manufacture product principal end customer product sale ixempra ixabepilone include alliance prior bms divestiture business fee pay otsuka base follow percentage combine annual net sale sprycel ixempra oncology territory include post divestiture ixempra sale net sale million million million million million million billion excess billion annual period otsuka contribute million certain commercial operational expense relate oncology product oncology territory cost excess million summarize financial information relate alliance follow year end december dollar million revenue otsuka alliance net product sale alliance revenuesa total revenue payment tofrom otsuka cost product sell oncology fee royalty cost product supply include amortization extension payment reduction alliance revenue million million lilly bms commercialization agreement lilly lillys subsidiary imclone codevelopment promotion erbitux canada japan party actively participate joint executive committee operating committee share responsibility research development resource infrastructure lilly manufacture bulk requirement erbitux facility filling finish perform party bms oversight responsibility bm exclusive distribution right north america responsible promotional effort north america lilly right copromote expense bms principal end customer product sale north america pay lilly distribution fee erbitux net sale north america plus share certain royalty pay lilly bmss right obligation respect commercialization erbitux north america expired september october bms transfer right erbitux north america lilly exchange salesbase royalty describe transfer right include limited commercialization manufacturing responsibility transaction account business divestiture result noncash charge million intangible asset directly relate business allocation goodwill bms receive royalty september include income earn royalty rate applicable north america erbitux net sale million million million million plus net sale excess amount respective year royalty earn million million bms share right erbitux japan agreement lilly merck kgaa receive pretax profit merck kgaas net sale erbitux japan share equally lilly bm transfer cocommercialization right japan merck kgaa exchange sale base royalty include income earn royalty earn million million summarize financial information relate alliance follow year end december dollar millions revenue lilly alliance net product sale alliance revenue total revenue payment tofrom lilly cost product sell distribution fee royalty amortization intangible asset cost product supply incomeexpense royalty divestiture loss astrazeneca prior diabetes business divestiture discuss bms alliance astrazeneca consist worldwide codevelopment commercialization agreement cover onglyza relate combination product sell name farxiga relate combination product begin august bms acquisition amylin amylin portfolio product include bydureon byetta symlin myalept certain asset own amylin include manufacturing facility locate west chester ohio coexclusive license right product product underlying agreement grant astrazeneca exchange upfront payment potential milestone payment party assume certain obligation actively participate alliance party actively participate joint executive committee operating committee joint responsibility research development distribution sale marketing activity alliance resource infrastructure bms manufacture product alliance principal end customer product sale substantially country alliance agreement right transfer astrazeneca standalone value right sell separately bms party astrazeneca receive benefit deliver right fulfillment ongoing obligation bms alliance agreement include exclusive supply arrangement global alliance treat single unit accounting result upfront proceed subsequent contingent milestone proceed amortize life relate product bms receive billion nonrefundable upfront payment astrazeneca consideration enter amylin alliance astrazeneca exercise option equal governance right certain key strategic financial decision amylin alliance pay bms million consideration payment account deferred income amortize base relative fair value predominant element include alliance estimate useful life intangible asset relate bydureon estimate useful life year byetta estimate useful life year symlin estimate life year myalept estimate useful life year amylin manufacture plant estimate useful life year amortization present reduction cost product sell alliance asset acquire shortly commencement alliance astrazeneca entitle share proceed sale asset amortization acquire amylin intangible asset manufacturing plant present cost product sell bms entitle reimbursement capital expenditure relate acquire amylin manufacturing facility bms astrazeneca share certain tax attribute relate amylin alliance prior termination alliance bms receive nonrefundable upfront milestone licensing payment million relate onglyza million relate farxiga amortization onglyza farxiga deferred income include income onglyza farxiga commercial product commencement alliance party share commercialization development expense equally profit loss february bms astrazeneca terminate alliance agreement bms sell astrazeneca substantially diabete business comprise alliance divestiture include share amylin result transfer ohio manufacturing facility intellectual property relate onglyza farxiga include bms interest outlicensing agreement onglyza japan purchase bmss manufacturing facility locate mount vernon indiana substantially employee dedicated diabetes business transfer astrazeneca bms astrazeneca enter agreement connection sale include supply agreement development agreement transitional service agreement agreement bms obligate supply certain product include active product ingredient onglyza farxiga perform ongoing development activity certain clinical trial program substantially provide transitional service account financial service customer service distribution regulatory development information technology certain administrative service period order facilitate orderly transfer business operation consideration transaction include billion payment close contingent regulatory salesbase milestone payment billion include million relate approval milestone million relate salesbased milestone payable royalty payment base net sale payment million certain asset transfer astrazeneca astrazeneca pay bms require product supply price approximating product cost negotiate transitional service fee royalty rate net sale follow onglyza farxiga worldwide net sale million onglyza farxiga worldwide net sale million amylin product net sale stock asset purchase agreement contain multiple element deliver subsequent closing transaction include china diabete business transfer mount vernon indiana manufacturing facility transfer activity development supply agreement element determine standalone value result portion consideration receive closing allocate undelivered element relative selling price method determine well estimate selling price element remain consideration include calculation gain sale diabete business contingent milestone royalty payment similarly allocate underlie element amount determined payable bms amount allocate sale business immediately recognize result operation amount allocate element recognize result operation extent element deliver consideration billion account include royalty million contingent regulatory milestone payment relate approval farxiga japan approximately billion consideration allocate sale business remain million allocate undelivered element describe consideration include million earn royalty include million allocate element deliver gain sale diabete business million include million quarter result primarily transfer china diabete business astrazeneca gain base difference consideration allocate sale business exclude royalty net transaction fee carry value diabete business net asset include million allocation goodwill reversal million net defer tax liability attribute amylin consideration million receive transfer mount vernon indiana manufacturing facility relate inventory result gain million amount allocate deliver element consideration allocate development supply agreement amortize applicable service period amortization defer income attribute development agreement include income sale service consider bmss ongoing major central operation revenue attribute supply agreement include alliance revenue consideration transaction present cash flow purpose base allocation process describe invest activity attribute sale business relate asset operating activity attribute transitional service supply arrangement development agreement september bm transfer percentage future royalty right amylin net product sale cppib transfer right represent approximately potential future royalty bms entitle exchange transfer bms receive additional tieredbase royalty amylin net product sale cppib royalty present income million summarize financial information relate astrazeneca alliance follow year end december dollar millions revenue astrazeneca alliance net product sale alliance revenue total revenue payment tofrom astrazeneca cost product sell profit sharing cost reimbursement astrazeneca incomeexpense amortization defer income royalty transitional service divestiture gain select alliance cash flow information defer income divestiture proceed select alliance balance sheet information december dollar millions defer income service perform astrazeneca sanofi bms sanofi codevelopment cocommercialization agreement plavix avaproavalide effective january sanofi assume essentially worldwide operation alliance exception plavix puerto rico bms operating partner control interest exchange right transfer sanofi bms receive quarterly royalty january december terminal payment sanofi million end royalty receive sanofi territory cover americas australia optout market development royalty present alliance revenues million million million royalty attribute territory cover europe asia continue earn territory partnership include equity net income affiliate alliance revenue attribute supply irbesartan api sanofi million million supply arrangement irbesartan expire summarize financial information relate alliance follow year end december dollar millions revenue sanofi alliance net product sale alliance revenue total revenue payment tofrom sanofi equity net income affiliate noncontrolle interest pretax select alliance cash flow information distribution tofrom sanofi noncontrolle interest distribution sanofi investment affiliate select alliance balance sheet information december dollar million investment affiliate territory cover europe asiaa noncontrolle interest include alliance receivables follow summarize financial information interest partnership sanofi territory cover europe asia consolidated account equity method year end december dollar million net sale gross profit net income cost product sell territory cover europe asia include discovery royalty million million million pay directly sanofi expense share base applicable ownership percentage current asset current liability include approximately million million million relate receivablespayable attribute cash distribution bms sanofi intercompany balance partnership territory ono bms principal end customer product sale exclusive right develop manufacture commercialize opdivo antipd human monoclonal antibody investigate anticancer treatment territory worldwide japan south korea taiwan ono entitle receive royalty follow regulatory approval territory exclude country list royalty rate net sale north america applicable territory subject customary adjustment alliance arrangement include collaboration activity japan south korea taiwan pertain opdivo yervoy bms investigational compound party right obligation jointly develop commercialize compound bms responsible supply product profit loss development cost share equally combination therapy involve compound party share activity involve party compound bms ono alliance codevelop cocommercialize orencia japan bms responsible order fulfillment distribution intravenous formulation ono responsible subcutaneous formulation formulation jointly promote party assign customer account bms responsible product supply copromotion fee pay party sale partys assign customer record cost product sell summarize financial information relate alliance follow year end december dollar millions revenue ono alliance net product sale alliance revenue total revenues abbvie bms abbvie alliance empliciti humanize monoclonal antibody treatment multiple myeloma term alliance bms grant exclusive global right codevelop commercialize empliciti pdl biopharma inc abbvie abbvie currently participate joint development commercialization committee bms final decision make authority party codevelope product abbvie fund global development cost bms solely responsible supply distribution sale marketing activity alliance principal end customer product sale abbvie share profit loss pay tiere royalty net sale empliciti outside bms pay abbvie million certain regulatory milestone event include million approval milestone december abbvie entitle receive additional milestone payment bms certain regulatory event occur million sale threshold achieve million agreement terminate bms party material breach party subsequent notice period summarize financial information relate alliance follow year end december dollar millions revenues abbvie alliance net product sale fstar october bms enter agreement fstar agreement provide bms exclusive option purchase fstar phase ready lead asset target therapy development treatment breast gastric cancer welldefine population herpositive patient bms pay million fstar shareholder consideration option grant certain licensing right include research development expense responsible conducting funding development option exercisable bms discretion expire early day follow obtain proof concept june additional million payable exercise option plus additional aggregate consideration million contingent development regulatory approval milestone payment europe bms obligate provide additional financial support fstar fstar determine business define asc business combination result contingent consideration include purchase price goodwill recognize fstar variable interest entity equity holder lack characteristic control financial interest bms determine primary beneficiary power direct activity significantly directly impact economic performance entity option right describe consolidation noncontrolle interest credit million reflect fair value iprd asset million defer tax liability promedior september bms purchase warrant give bms exclusive right acquire promedior biotechnology company lead asset prm develop treatment ipf warrant exercisable completion ipf phase clinical study conduct promedior expect occur early upfront payment allocate warrant million include expense remain million million upfront payment allocate promedior obligation complete phase study amortize expect period phase study allocation determine level input follow bms review phase clinical study result bms elect exercise warrant obligate pay additional million base ipf study result million base study result plus additional aggregate consideration million contingent development regulatory approval milestone payment europe prime november bms prime enter exclusive worldwide licensing collaboration agreement development commercialization prime csfr antibody program include cabiralizumab fpa currently phase iii development immunology oncology indication bms responsible development manufacturing commercialization cabiralizumab subject prime option conduct certain study cost develop cabiralizumab pvns combination internal oncology pipeline asset prime retain option copromote agreement replace previous clinical collaboration agreement party consideration licensing right bms upfront payment million include expense bms commit pay billion achievement contingent development regulatory milestone future royalty product approve commercialize reckitt bms reckitt start threeyear alliance otc product sell primarily mexico brazil reckitt receive right sell distribute market product bms receive royalty net sale product exclusively supply certain product reckitt pursuant supply agreement cost plus markup certain limited asset include marketing authorization certain employee directly attribute business transfer reckitt start alliance period bms retain ownership asset relate business include trademark cover product framework alliance bms grant reckitt option acquire trademark inventory certain asset exclusively relate product end alliance period price determine primarily base multiple sale april alliance modify provide option reckitt purchase bms manufacturing facility locate mexico primarily dedicated product include alliance related employee july reckitt notify bms exercise option bms sell business million refer note acquisition divestiture information nonrefundable upfront proceed million receive bms allocate unit account include right transfer reckitt fair value option purchase remain asset good estimate sell price element consider market factor market factor include analysis estimate excess fair value business potential purchase price option exercise fair value option determine level input include liability bms recognize income million decrease fair value option zero strengthen dollar local currency allocate right transfer reckitt amortize alliance revenue contractual term summarize financial information relate alliance follow year end december dollar millions revenues reckitt alliance alliance revenues incomeexpense divestiture gain select alliance cash flow information change operate asset liability divestiture proceed select alliance balance sheet information december dollar millions defer income medicine company february bms medicine company enter twoyear alliance recothrom recombinant thrombin use topical hemostat control nonarterial bleed surgical procedure previously acquire bms connection acquisition zymogenetics inc medicine company receive right sell distribute market recothrom global basis year bms exclusively supply recothrom medicine company cost plus markup receive royalty net sale recothrom certain employee directly attribute business certain asset transfer medicine company start alliance period include biologic license application relate regulatory asset bms retain asset relate recothrom include patent trademark inventory bms grant medicine company option acquire patent trademark inventory certain asset exclusively relate recothrom price determine base multiple sale plus cost remain inventory hold bms time medicine company exercise option acquire business million february nonrefundable upfront proceed million receive bms allocate unit account include right transfer medicine company fair value option purchase remain asset good estimate sell price element consider market factor market factor include analysis estimate excess fair value business potential purchase price option exercise fair value option million december determine level input include accrue expense allocate right transfer medicine company amortize alliance revenue contractual term summarize financial information relate alliance follow year end december dollar millions revenue medicines company alliance alliance revenues incomeexpense divestiture gain select alliance cash flow information divestiture proceed valeant october bms pharmaswis whollyowne subsidiary valeant enter alliance certain mature brand product europe valeant receive right sell distribute market product europe december bms exclusively supply product valeant cost plus markup bms grant valeant option acquire trademark intellectual property exclusively relate product price determine base multiple sale valeant exercise option acquire business million january nonrefundable upfront proceed million receive bms allocate unit account include right transfer valeant fair value option purchase remain asset good estimate sell price element consider market factor market factor include analysis estimate excess fair value business potential purchase price option exercise fair value option determine level input include accrue expense million charge include expense increase fair value option million allocate right transfer valeant amortize alliance revenue contractual term summarize financial information relate alliance follow year end december dollar millions revenue valeant alliance alliance revenues incomeexpense divestiture gain select alliance cash flow information change operate asset liability divestiture proceed note acquisition divestiture acquisition acquisition evaluate determine business asset group asset follow transaction account asset acquisition determined business term define asc business combination primarily significant process acquire result amount allocate lead investigational compound expense capitalize consideration transaction allocate follow contingent dollar millions year upfront payment expense defer tax assetsa consideration cormorant padlock cardioxyl flexusb ipierian relate net operating loss tax credit carryforward include million acquisition cost cormorant july bms acquire outstanding share cormorant private pharmaceutical company focus development therapy cancer rare disease acquisition provide bms right cormorant lead candidate humaxil phase iii monoclonal antibody represent potentially complementary immunooncology mechanism action tcell direct antibodie costimulatory molecule contingent consideration include development regulatory milestone payment padlock april bms acquire outstanding share padlock private biotechnology company dedicate create new medicine treat destructive autoimmune disease acquisition provide bms right padlock pad inhibitor discovery program focus development potentially transformational treatment approach patient rheumatoid arthritis padlock pad discovery program additional utility treat systemic lupus erythematosus autoimmune disease contingent consideration include development regulatory milestone payment cardioxyl december bms acquire outstanding share cardioxyl private biotechnology company focus discovery development novel therapeutic agent cardiovascular disease acquisition provide bms right cxl nitroxyl prodrug phase development acute decompensate heart failure contingent consideration include development regulatory salesbase milestone payment flexus april bms acquire outstanding share flexus private biotechnology company focus discovery development novel anti cancer therapeutic acquisition provide bms right preclinical small molecule idoinhibitor target immunotherapy addition bms acquire flexus idotdo discovery program include idoselective idotdo dual tdoselective compound contingent consideration include development regulatory milestone payment million milestone achieve pay shareowner flexus commencement phase clinical trial include expense ipierian april bms acquire outstanding share ipierian private biotechnology company focus new treatment tauopathie class neurodegenerative disease acquisition provide bms right ipn preclinical monoclonal antibody treat progressive supranuclear palsy tauopathie contingent consideration include development regulatory milestone payment future royalty net sale acquire preclinical asset approve commercialize divestiture proceedsa divestiture gain loss royaltie dollar millions investigational hiv medicine otc product reckitt diabetes erbitux recothrom mature brand product valeant ixempra include royalty receive subsequent relate sale asset business viiv healthcare february bms sell investigational hiv medicine business viiv healthcare include number program different stage discovery preclinical clinical development transaction exclude bms hiv market medicine bms earn transitional fee million certain service february bms receive upfront payment million bm receive viiv healthcare contingent development regulatory milestone payment billion salesbase milestone payment billion future tiere royalty product approve commercialize divestiture refer note alliance discussion divestiture transaction reckitt lilly medicines company valeant astrazeneca revenue pretax earning relate business material exclude divestiture gain asset heldforsale asset heldforsale million december include prepay expense consist primarily goodwill relate investigational hiv medicine business business comprise alliance reckitt allocation goodwill determine relative fair value applicable business company reporting unit revenue pretax earning relate business material exclude divestiture gain note incomeexpense incomeexpense include year end december dollar million interest expense investment income provision restructure litigation settlement equity net income affiliate divestiture gain royalty license income transition service fee pension charge intangible asset impairment equity investment impairment write option adjustment loss debt redemption incomeexpense litigation settlement include million contractual dispute relate license transition service fee relate divestiture diabete investigational hiv business diabete business write option adjustment include change fair value write option liability attribute reckitt alliance valeant reckitt debt redemption loss million result early redemption euro note tender offer certain debt security include unrealized foreign exchange loss million result remeasurement bolivardenominate cash monetary balance bmss whollyowne subsidiary venezuela december exchange rate change simadi rate official cencoex rate consider limited foreign currency exchange second half publish exchange rate continue deterioration economic condition venezuela note restructuring october company announce restructure evolve streamline operating model expect incur charge connection employee workforce reduction early site exit charge expect incur range billion billion consist employee termination benefit cost contract termination cost accelerate depreciation property plant equipment impairment longlive asset site shutdown cost cash outlay connection action expect approximately total charge charge approximately million recognize action fourth quarter primarily result certain employee workforce reduction accelerate depreciation expect early site exit restructuring charge recognize meet certain criterion include finalization commit plan reliable estimate discussion local work council certain market restructure charge recognize prior action primarily relate specialty care transformation initiative design create simplify organization function geographic market addition accelerate depreciation charge incur connection early exit manufacturing site ireland site employee termination benefit cost incur manufacturing sell administrative employee workforce reduction geographic region approximately follow table summarize charge activity relate restructuring action year end december dollar million employee termination cost termination cost provision restructuring accelerate depreciation asset impairment shutdown cost total charge year end december dollar million cost product sell research development incomeexpense total charge year end december dollar million liability january charge change estimate provision restructure foreign currency translation spending liability december note income taxis provisionbenefit income taxis consist year end december dollar millions current nonus total current defer nonus total defer total provision effective tax rate reconciliation effective taxbenefit rate statutory federal income tax rate earning income taxis dollar million earningsloss income taxis nonus total statutory rate foreign tax effect certain operation ireland puerto rico switzerland tax effect capital loss federal valuation allowance release federal state foreign contingent tax matter federal research base credit goodwill allocate divestiture brand prescription drug fee charge puerto rico excise tax domestic manufacturing deduction state local taxis net valuation allowance foreign effective tax rate low statutory rate primarily attributable undistributed earning certain foreign subsidiary consider expect indefinitely reinveste offshore taxis provide approximately billion undistributed earning foreign subsidiary december undistribute earning primarily relate operation switzerland ireland puerto rico undistribute earning repatriate future determine earning remit foreseeable future additional tax provision require complexity tax law assumption practicable estimate amount income taxis provide bms operate favorable tax grant puerto rico schedule expire prior divestiture certain business result capital loss tax benefit include million sale amylin share valuation allowance attribute capital loss carryforward release follow divestiture recothrom ixempra mature brand additional reserve million establish certain transfer pricing matter related tax period orphan drug credit include federal research base credit period present goodwill allocate business divestiture include diabetes business deductible tax purpose brand prescription drug fee period charge result primarily milestone payment shareholder flexus acquisition padlock cormorant flexus cardioxyl ipierian deductible tax purpose puerto rico imposes excise tax gross company purchase price good sell manufacturer puerto rico excise tax recognize cost product sell intraentity sale occur income tax purpose excise tax deductible result foreign tax credit generally recognize provision income taxis excise tax incur increase manufacturing activity opdivo result high domestic manufacturing deduction defer taxis valuation allowance component current noncurrent defer income tax assetsliabilitie follow december dollar millions defer tax asset foreign net operating loss carryforward capital loss carryforward state net operating loss credit carryforward federal net operating loss credit carryforward defer income milestone payment license fee pension postretirement benefit intercompany profit inventory item foreign defer tax asset sharebase compensation legal settlement repatriation foreign earning internal transfer intellectual property total defer tax asset valuation allowance defer tax asset net valuation allowance defer tax liability depreciation acquire intangible asset goodwill total defer tax liability defer tax asset net recognize deferred income taxis noncurrent income taxis payable noncurrent total internal transfer intellectual property result defer tax asset include prepay taxis million december million prepay taxis december asset amortize expect life refer recently issue accounting standard note accounting policy information impact amend guidance company expect adopt federal net operating loss carryforward million december carryforward acquire result certain acquisition subject limitation section internal revenue code net operating loss carryforward expire vary amount begin foreign state net operating loss carryforward expire vary amount begin certain amount unlimited life december valuation allowance million establish follow item million primarily foreign net operating loss tax credit carryforward million state defer tax asset include net operating loss tax credit carryforward million federal net operating loss carryforward million federal defer tax asset change valuation allowance follow year end december dollar million balance begin year provision utilization foreign currency translation acquisition balance end year income tax payment million million million current tax benefit realize result stock relate compensation credit capital excess par value stock million million million business conduct country world subject tax numerous jurisdiction significant number tax return file subject examination federal state local tax authority tax examination complex tax authority disagree treatment item report require year resolve liability establish possible assessment tax authority result know tax exposure include limited transfer pricing matter tax credit deductibility certain expense liability represent reasonable provision taxis ultimately expect pay need adjusted time information know effect change estimate related contingent tax liability include effective tax rate reconciliation reconciliation begin end gross unrecognized tax benefit follow year end december dollar million balance begin year gross addition tax position relate current year gross addition tax position relate prior year gross addition tax position assume acquisition gross reduction tax position relate prior year settlement reduction tax position relate lapse statute cumulative translation adjustment balance end year additional information unrecognized tax benefit follow year end december dollar millions unrecognized tax benefit recognize impact effective tax rate accrue interest accrue penalty interest expense penalty expensebenefit accrue interest penalty payable unrecognized tax benefit include current noncurrent income taxis payable interest penalty relate unrecognized tax benefit include income tax expense bms currently examination number tax authority include limited major tax jurisdiction list table propose consider propose material adjustment tax issue transfer price certain tax credit deductibility certain expense bms estimate reasonably possible total unrecognized tax benefit december decrease range approximately million million month result settlement certain tax audits event expect change unrecognized tax benefit primarily settlement related involve payment additional taxis adjustment certain defer taxis andor recognition tax benefit reasonably possible new issue raise tax authority increase unrecognized tax benefit estimate increase reasonably time bms believe adequately provide open tax year tax jurisdiction follow summary major tax jurisdiction tax authority assert additional taxis base tax year currently audit subsequent year likely audit canada france germany italy mexico note earning share year end december amount million share datum net earning attributable bms basic diluted eps calculation weightedaverage common share outstanding basic contingently convertible debt common stock equivalent incremental share attributable sharebased compensation plan weightedaverage common share outstanding diluted earning share basic earning share dilute note financial instrument fair value measurement financial instrument include cash cash equivalent marketable security account receivable payable debt instrument derivative change exchange rate interest rate create exposure market risk certain derivative financial instrument available costeffective basis hedge underlie economic exposure instrument qualify cash flow net investment fair value hedge meet certain criterion include effectiveness offset hedge exposure change fair value derivative qualify hedge accounting recognize earning occur derivative financial instrument trading purpose financial instrument subject counterparty credit risk consider overall fair value measurement counterparty credit risk monitor ongoing basis mitigate limiting amount outstanding individual counterparty utilize conventional derivative financial instrument enter agreement counterpartie meet high credit quality standard consolidate financial statement materially impact counterparty fail perform accord term agreement collateral require party derivative asset liability position term agreement fair value measurement fair value financial instrument classify follow category level input utilize unadjusted quote price active market accessible measurement date identical asset liability fair value hierarchy provide high priority level input level input utilize observable price similar instrument quote price identical similar instrument nonactive market additionally certain corporate debt security utilize thirdparty matrix pricing model significant input corroborate market datum substantially term asset equity fix income fund primarily invest publicly trade security value respective net asset value underlie investment level derivative instrument value libor yield curve credit valuation adjustment observable forward foreign exchange rate report date valuation derivative contract fluctuate considerably volatility underlie foreign currency underlie interest rate drive market condition duration contract level unobservable input little market datum available level financial asset liability december financial asset liability measure fair value recur basis summarize december december dollar million level level level level cash cash equivalent money market security marketable security certificate deposit commercial paper corporate debt security equity fund fix income fund derivative asset equity investment derivative liability availableforsale security follow table summarize availableforsale security gross gross unrealize unrealized gain loss amortize accumulate accumulate dollar million cost oci oci fair value december certificate deposit commercial paper corporate debt security equity investment total december certificate deposit corporate debt security equity investment total december december dollars million current marketable securitiesa noncurrent marketable securitiesb asset total fair value option financial asset elect investment equity fix income fund fair value investment million december million december include current marketable security change fair value significant ball noncurrent marketable security mature year december qualifying hedge follow summarize fair value outstanding derivative december december dollar million balance sheet location notional fair value notional fair value derivative designate hedge instrument interest rate swap contract prepaid expense interest rate swap contract asset interest rate swap contract accrue liability interest rate swap contract pension liability forward start interest rate swap contract prepaid expense forward start interest rate swap contract asset forward start interest rate swap contract accrue liability forward start interest rate swap contract pension liability foreign currency forward contract prepay expense foreign currency forward contract accrue liability derivative designate hedge instrument foreign currency forward contract prepay expense foreign currency forward contract accrue liability foreign currency forward contract pension liability cash flow hedge foreign currency forward contract hedge certain forecast intercompany inventory purchase transaction certain foreign currency transaction effective portion change fair value contract designate cash flow hedge temporarily report accumulate comprehensive loss include earning hedge item affect earning net gain foreign currency forward contract expect reclassify net earning primarily include cost product sell year notional outstanding foreign currency forward contract primarily attribute euro million japanese yen million december bm enter million forward start interest rate swap contract mature march hedge variability probable forecast interest expense associate potential future issuance debt contract designate cash flow hedge effective portion fair value change include comprehensive income earning impact relate discontinued cash flow hedge hedge ineffectiveness significant period present cash flow hedge accounting discontinue forecast transaction long probable occur day originally forecast date hedge long effective assessment determine derivative designate qualifying hedge highly effective offset change cash flow hedge item perform inception quarterly basis net investment hedge nonus dollar borrowing million million december designate hedge foreign currency exposure net investment certain foreign affiliate borrowing designate net investment hedge recognize long term debt effective portion foreign exchange gain remeasurement euro debt million million million respectively record foreign currency translation component accumulate comprehensive loss relate offset longterm debt fair value hedge fixedtofloate interest rate swap contract designate fair value hedge interest rate risk management strategy create appropriate balance fix float rate debt contract underlie debt hedge benchmark risk record fair value effective interest rate contract onemonth libor december plus interest rate spread range underlying swap terminate prior maturity fair value basis adjustment underlie debt instrument amortize reduction interest expense remain life debt notional fixedtofloate interest rate swap contract execute million million notional fixedto float interest rate swap contract terminate million million million generating proceed million million million include accrue interest additional contract terminate connection debt redemption debt obligation shortterm borrowing current portion longterm debt include december dollar millions bank draft shortterm borrowing current portion longterm debt total average commercial paper outstanding million weightedaverage interest rate maximum month end commercial paper outstanding million outstanding borrowing december commercial paper borrowing longterm debt current portion longterm debt include december dollar million principal value note note note note note euro note note euro note note note note note note mature subtotal adjustment principal value fair value interest rate swap contract unamortize basis adjustment swap termination unamortized bond discount issuance cost total current portion longterm debt longterm debt fair value longterm debt million million december respectively estimate level input base quote market price similar debt instrument fair value shortterm borrowing approximate carry value short maturity debt instrument senior unsecured note issue register public offering notes rank equally right payment bms exist future senior unsecured indebtedness redeemable time predetermine redemption price bms terminate forward start interest rate swap contract enter result unrealized loss comprehensive income follow table summarize issuance longterm debt obligation amount million euro dollar principal value euro note euro note total proceed net discount defer loan issuance cost forward start interest rate swap contract terminate notional unrealize loss follow summarize debt redemption activity dollar million principal carry value debt redemption price notional interest rate swap contract terminate interest rate swap termination payment loss debt redemptiona ainclude acceleration debt issuance cost loss interest rate lock contract relate fee interest payment million million million net amount receive interest rate swap contract currently separate billion revolving credit facility syndicate lender facility provide customary term condition financial covenant extend october july facility extendable annually year anniversary date consent lender borrowing outstanding revolve credit facility december available financial guarantee provide form standby letter credit performance bond million december standby letter credit issue financial institution support guarantee obligation performance bond issue support range ongoing operating activity include sale product hospital foreign ministry health bond custom duty value add tax guarantee relate miscellaneous legal action significant majority outstanding financial guarantee expire year expect fund note receivable december dollar million trade receivable chargeback cash discount bad debt allowance net trade receivables alliance receivables prepay refundable income taxis receivables nonus receivables sell nonrecourse basis million million million aggregate receivable pharmaceutical wholesaler represent total trade receivables december respectively change allowance bad debt chargeback cash discount follow year end december dollar million balance begin year provision utilization balance end year note inventory december dollar million finished good work process raw packaging material inventory inventory asset asset include inventory pende regulatory approval million december million december amount expect remain onhand year note property plant equipment lease december dollar million land building machinery equipment fixture construction progress gross property plant equipment accumulate depreciation property plant equipment depreciation expense million million million annual minimum rental commitment noncancelable operating lease primarily real estate motor vehicle approximately million year aggregate million operate lease expense approximately million million sublease income capital lease obligation material period present note goodwill intangible asset december estimate dollar million useful life goodwill intangible asset license year develop technology right year capitalize software year iprd gross intangible asset accumulate amortization total intangible asset amortization expense intangible asset million million million future annual amortization expense intangible asset expect approximately million million million million million intangible asset impairment charge million million million million iprd impairment charge recognize bms lpa antagonist phase development treatment ipf writeoff require consider occurrence certain adverse event voluntary suspension study internal assessment indicate significantly low likelihood regulatory commercial success bms acquire bms acquisition amira pharmaceuticals inc addition contingent consideration liability million relate acquisition reverse low likelihood success million iprd impairment charge recognize peginterferon lambda phase iii development treatment hcv writeoff require assess potential commercial viability asset estimate fair value assessment consider low likelihood file registration certain market complete revise projection revenue expense significant decline prior project revenue result global introduction oral noninterferon product treat patient hcv alternative use product note accrue liability december dollars millions accrue rebate return employee compensation benefit accrue research development dividend payable royalty brand prescription drug fee restructure pension postretirement benefit litigation settlement total accrue liability note equity common stock capital accumulate treasury stock excess par value comprehensive retain noncontrolle dollar share million share par value stock loss earning share cost interest balance january net earning comprehensive loss cash dividend stock compensation debt conversion variable interest entity distribution balance december net earning comprehensive loss cash dividend stock compensation debt conversion distribution balance december net earning comprehensive loss cash dividend stock repurchase program stock compensation distribution balance december treasury stock recognize cost reacquire share share issue treasury recognize utilize firstin firstout method october board director approve new share repurchase program authorize repurchase additional billion common stock repurchase open market private transaction include repurchase plan establish accordance rule securities exchange act stock repurchase program expiration date suspend discontinue time february bms enter asr agreement goldman sachs morgan stanley llc repurchase approximately billion common stock aggregate asr fund combination debt cash exist share repurchase authorization total number share ultimately repurchase asr determine final settlement base discount volumeweighte average price bms common stock asr period expect complete june components comprehensive incomeloss follow year end december dollar million pretax tax tax pretax tax tax pretax tax tax derivative qualify cash flow hedgesa unrealize gainslosse reclassify net earning derivative qualify cash flow hedge pension postretirement benefit actuarial loss amortizationb settlement curtailmentsc pension postretirement benefit availableforsale security unrealize gainslosse realize gainslossesc availableforsale security foreign currency translation total comprehensive incomeloss include cost product sell include cost product sell research development marketing sell administrative expense include incomeexpense accumulate balance relate component comprehensive loss net taxis follow december dollar million derivative qualify cash flow hedge pension postretirement benefit availableforsale security foreign currency translation accumulate comprehensive loss note pension postretirement benefit plan bms sponsor define benefit pension plan define contribution plan termination indemnity plan regular fulltime employee principal define benefit pension plan bristolmyers squibb retirement income plan cover employee represent approximately consolidated pension plan asset obligation future benefit relate service plan eliminate bms contribute minimum require erisa plan benefit base primarily participant year credit service final average compensation plan asset consist principally equity fixedincome security net periodic benefit costcredit define benefit pension plan include dollar million service cost benefit earn year interest cost project benefit obligation expect return plan asset amortization prior service credit amortization net actuarial loss curtailment settlement special termination benefit net periodic benefit costcredit september bms fiduciary counselors inc independent fiduciary bristolmyers squibb company retirement income plan enter definitive agreement transfer certain pension asset prudential settle approximately billion pension obligation bms purchase group annuity contract prudential december irrevocably assume obligation future annuity payment certain bms retiree transaction change monthly pension benefit receive affected retiree survive beneficiary result pretax settlement charge million pension settlement charge recognize determine annual lump sum payment exceed annual interest service cost certain pension plan include primary pension plan change define benefit pension plan obligation asset fund status amount recognize consolidated balance sheet follow dollar million benefit obligation begin year service costbenefit earn year interest cost settlement actuarial gainslosse benefit pay foreign currency benefit obligation end year fair value plan asset begin year actual return plan asset employer contribution settlement benefit pay foreign currency fair value plan asset end year fund status assetsliabilitie recognize asset accrue liability pension liability fund status recognize accumulate comprehensive loss net actuarial loss prior service credit total accumulate benefit obligation define benefit pension plan million million december respectively additional information relate pension plan follow dollar million pension plan project benefit obligation excess plan asset project benefit obligation fair value plan asset pension plan accumulate benefit obligation excess plan asset accumulate benefit obligation fair value plan asset actuarial assumption weightedaverage assumption determine define benefit pension plan obligation december follow discount rate rate compensation increase weightedaverage actuarial assumption determine define benefit pension plan net periodic benefit creditcost year end december follow discount rate expect longterm return plan asset rate compensation increase yield high quality corporate bond match duration benefit obligation determine discount rate citi pension discount curve develop discount rate plan expect return plan asset determine expect rate return calculate value asset refer marketrelated value approximate fair value plan asset december difference assume actual return amortize marketrelated value straightline basis threeyear period factor consider develop expect return plan asset include longterm historical return input external advisor individual asset class return forecast develop base market condition example priceearning level yield longterm growth expectation expect longterm rate return weightedaverage target asset allocation individual asset class historical longterm actual annualize return pension plan follow year year year actuarial gain loss result change actuarial assumption change discount rate revise mortality rate difference assume actual experience difference actual expect return plan asset gain loss amortize life expectancy plan participant plan year expect remain service period plan extent exceed high marketrelated value project benefit obligation respective plan amortization net actuarial loss prior service credit expect approximately million periodic benefit cost credit include cost product sell research development marketing sell administrative expense curtailment settlement special termination benefit include expense postretirement benefit plan comprehensive medical group life benefit provide substantially retiree elect participate comprehensive medical group life plan less extent certain benefit nonus employee medical plan contributory contribution adjust periodically vary date retirement life insurance plan noncontributory plan asset consist principally equity fixedincome securities postretirement benefit plan obligation million million december respectively fair value plan asset million million december respectively weightedaverage discount rate determine benefit obligation december net periodic benefit credit material plan asset fair value pension postretirement plan asset asset category december follow december december dollar million level level level total level level level total plan asset equity security equity fund fix income fund corporate debt security treasury agency security shortterm investment fund insurance contract cash cash equivalent plan asset subject leveling plan asset measure nav practical expedient equity fund venture capital limited partnership total plan asset measure nav practical expedient net plan asset investment valuation policy investment class follow level input utilize unadjusted quote price active market accessible measurement date identical asset liability fair value hierarchy provide high priority level input instrument include equity security equity fund fix income fund publicly trade national security exchange cash cash equivalent cash cash equivalent highly liquid investment original maturity month time purchase recognize cost approximate fair value pende trade sale purchase include cash cash equivalent final settlement level input utilize observable price similar instrument quote price identical similar instrument nonactive market observable input corroborate market datum substantially term asset liabilitie equity fund fix income fund shortterm investment fund classify level fair value hierarchy value net asset value share hold year end represent fair value corporate debt security treasury agency security classify level fair value hierarchy value utilize observable price similar instrument quote price identical similar instrument market active level unobservable input little market datum available insurance contract hold certain foreign pension plan carry contract value approximate estimate fair value base fair value underlie investment insurance company fasb issue amend guidance remove requirement categorize fair value hierarchy investment fair value measure nav share equivalent practical expedient guidance apply retrospectively table venture capital limited partnership investment typically redeemable distribution liquidation underlie asset significant unfunded commitment investment essentially liquidation expect occur remain investment practical expedient redeemable weekly monthly basis follow summarize activity financial asset utilize level fair value measurement dollar million insurance contract fair value january purchase sale settlement net realize loss fair value december purchase sale settlement net fair value december investment strategy maximize return maintain appropriate level risk provide sufficient liquidity benefit obligation plan expense target asset allocation public equity international global private equity longduration fix income maintain pension plan investment diversify major asset category approximately pension plan equity investment actively manage bms common stock represent plan asset december contribution estimate future benefit payment contribution pension plan million million million expect approximately million estimate annual future benefit payment include lump sum payment range approximately million million year aggregate billion subsequent year period saving plan principal define contribution plan bristolmyer squibb saving investment program contribution base employee contribution level company match expense attribute define contribution plan approximately million note employee stock benefit plan shareholder approve plan replace stock incentive plan plan provide million share authorize grant plus share outstanding award plan february expire forfeit cancel withhold satisfy tax withholding obligation december million share available award share issue treasury stock satisfy obligation plan executive officer key employee grant option purchase common stock market price date option grant option generally exercisable ratably year maximum term year plan provide grant stock appreciation right grantee surrender exercisable right receive common stock andor cash measure excess market price common stock option exercise price company grant stock option stock appreciation right restrict stock unit grant key employee subject restriction continuous employment generally vest occur ratably year period grant date stock unit right receive stock end specify vest period voting right market share unit grant executive vest condition continuous employment vest date payout factor share price award date payout factor share price vest date divide share price award date maximum share price payout factor calculate average closing price grant vest date trading day immediately precede grant vest date vest occur ratably year performance share unit grant executive year cycle grant target number unit subject adjustment number share issue performance share unit vest determine base achievement performance goal base company threeyear total shareholder return relative peer group company vest condition continuous employment occur anniversary grant date stockbase compensation expense award ultimately expect vest recognize vest period forfeiture estimate base historical experience time grant revise subsequent period actual forfeiture differ estimate information relate stockbase compensation benefit follow year end december dollar million restrict stock unit market share unit performance share unit total stockbase compensation expense income tax benefit stock option restrict stock unit market share unit performance share unit weight number weight number weight number weight number average average average average option exercise price nonveste grantdate nonveste grantdate nonveste grantdate share thousand outstanding share awards fair value award fair value award fair value balance january grant releasedexercised adjustment actual payout forfeitedcancele balance december vest expect vest restrict market performance dollar million stock unit share unit share unit unrecognize compensation cost expect weightedaverage period year compensation cost recognize amount million share datum weightedaverage grant date fair value share restrict stock unit market share unit performance share unit fair value award vest restricted stock unit market share unit performance share unit total intrinsic value stock option exercise fair value restrict stock unit market share unit performance share unit approximate close trading price bms common stock grant date adjust unit eligible accrue dividend addition fair value market share unit performance share unit consider probability satisfy payout factor total shareholder return respectively follow table summarize significant range outstanding exercisable option december option outstanding exercisable number weightedaverage weightedaverage aggregate outstanding exercisable remain contractual exercise price intrinsic value range exercise price thousand life year share million aggregate intrinsic value precede table represent total pretax intrinsic value base close stock price december note legal proceeding contingency company certain subsidiary involve lawsuit claim government investigation legal proceeding arise ordinary course business claim proceeding involve type party include government competitor customer supplier service provider licensee employee shareholder resolution matter develop long period time expectation change result new finding ruling appeal settlement arrangement company recognize accrual contingency probable liability incur loss reasonably estimate matter involve patent infringement antitrust security pricing sale marketing practice environmental commercial contractual right licensing obligation health safety matter consumer fraud employment matter product liability insurance coverage legal proceeding material company believe material describe company believe substantial defense matter assurance increase scope pende matter future lawsuit claim government investigation legal proceeding material note company unable assess outcome respective litigation able provide estimate range potential loss furthermore failure enforce patent right likely result substantial decrease respective product revenue generic competition intellectual property plavix australia previously disclose sanofi notify august genrx proprietary limited genrx obtain regulatory approval application clopidogrel bisulfate tablets australia genrx subsidiary apotex inc apotex change apotex august apotex file application federal court australia federal court seek revocation sanofis australian patent case nsd sanofi file counterclaims infringement seek injunction september federal court grant sanofis injunction subsidiary company subsequently add party proceeding february second company spirit pharmaceuticals pty ltd file revocation suit patent case consolidate apotex case trial occur april august federal court australia hold claim patent cover clopidogrel bisulfate hydrochloride hydrobromide taurocholate salt valid federal court hold process claim pharmaceutical composition claim claim direct clopidogrel pharmaceutically acceptable salt invalid company sanofi file notice appeal court federal court australia court appeal hold invalidity claim cover clopidogrel pharmaceutically acceptable salt process claim pharmaceutical composition claim stay federal court rule apotex file notice appeal appeal hold validity clopidogrel bisulfate hydrochloride hydrobromide taurocholate claim hearing appeal occur february september court hold claim patent invalid november company sanofi apply high court australia high court special leave appeal judgment court march high court deny company sanofis request hear appeal court decision case remand federal court proceeding relate damage seek apotex australian government intervene matter seek damage allege loss experience period injunction place company apotex settle apotex case case dismiss australian government claim pende trial schedule august possible time predict outcome australian government claim impact company sprycel european union apotex actavis group ptc ehf generics limited mylan unnamed company file opposition european patent office epo seek revocation european patent patent cover dasatinib active ingredient sprycel patent schedule expire april exclude potential term extension january opposition division epo revoke patent company appeal epos decision epo board appeal february epo board appeal uphold opposition division decision patent revoke orphan drug exclusivity datum exclusivity sprycel expire november epo board appeal decision affect validity sprycel patent outside europe include different patent cover monohydrate form dasatinib use dasatinib treat chronic myelogenous leukemia cml additionally february epo board appeal reverse remand invalidity decision european patent claim use dasatinib treat cml epo opposition division revoke october company intend appropriate legal action protect sprycel experience decline european revenue event generic dasatinib product enter market antipd antibody patent opposition litigation january bms ono announce company sign global patent license agreement merck settle patentinfringement litigation relate merck antibody keytruda pembrolizumab agreement result dismissal prejudice patent litigation company pertain keytruda bms ono assert litigation merck sale keytruda infringe company patent relate use antibody treat cancer europe netherlands france germany ireland spain switzerland australia japan agreement merck initial payment million bms ono merck obligate pay ongoing royalty global sales keytruda january december january december agreement company grant certain right respective patent portfolio pertain initial payment royalty share bms ono percent allocation respectively adjust party incur legal fee september danafarber cancer institute danafarber file complaint massachusetts federal court seek correct inventorship relate patent direct method treat cancer antibody specifically danafarber seeking add scientist inventor patent price sale promotional practice litigation plavix state attorney general lawsuit company certain affiliate sanofi defendant consumer protection andor false advertising action bring state relate sale promotion plavix possible time reasonably assess outcome lawsuit potential impact company product liability litigation company party product liability lawsuit plaintiff case seek damage relief ground allege personal injury economic loss previously disclose addition lawsuit company face unfiled claim involve product plavix previously disclose company certain affiliate sanofi defendant number individual lawsuit state federal court claim personal injury damage allegedly sustain plavix currently claim involve injury plaintiff claim spouse andor beneficiary file state federal court state include california new jersey delaware new york february judicial panel multidistrict litigation grant company sanofis motion establish multidistrict litigation mdl coordinate federal pretrial proceeding plavix product liability relate case new jersey federal court possible time reasonably assess outcome lawsuit potential impact company byetta amylin subsidiary company lilly codefendant product liability litigation relate byetta date separate lawsuit pende behalf approximately active plaintiff include pende settlement include injury plaintiff claim spouse andor beneficiary court company agree principle resolve claim majority case bring individual allege personal injury sustain byetta primarily pancreatic cancer pancreatitis case claim alleged wrongful death majority case pende federal court san diego mdl coordinated proceeding california superior court los angeles jccp november defendant motion summary judgment base federal preemption grant mdl jccp plaintiffs mdl appeal court appeal ninth circuit jccp plaintiff appeal california court appeal amylin product liability insurance cover substantial number claim involve byetta additional liability amylin respect byetta expect share company astrazeneca possible reasonably predict outcome lawsuit claim proceed potential impact company abilify company otsuka codefendant product liability litigation relate abilify plaintiff allege abilify cause engage compulsive gambling impulse control disorder approximately case file state federal court additional case pende canada judicial panel multidistrict litigation consolidated federal court case pretrial purpose united states district court northern district florida eliquis company pfizer codefendant product liability litigation relate eliquis plaintiff assert claim include claim wrongful death result bleed allege cause use eliquis case file state federal court unite states case file canada judicial panel multidistrict litigation consolidated federal court case pretrial purpose united states district court southern district new york shareholder derivative litigation december shareholder derivative lawsuit file new york state court certain officer director company plaintiff allege thing breach fiduciary duty surround company previously disclose october civil settlement securities exchange commission allege foreign corrupt practice act violation china company agree payment approximately million disgorgement penalty interest company file motion dismiss shareholder derivative lawsuit government investigation like pharmaceutical company company certain subsidiary subject extensive regulation national state local government agency country bms operate result company time time subject governmental inquiry investigation possible criminal charge substantial fine andor civil penalty result government investigation significant investigation conduct government agency company aware list abilify state attorney general investigation march company receive letter delaware attorney general office advise multistate coalition coalition investigate certain abilify marketing practice violate respective state consumer protection statute company executive committee coalition reach settlement matter state new mexico member coalition participate settlement consent decree enter participate state december environmental proceeding previously report company party environmental proceeding matter responsible state federal foreign law include cercla certain cost investigate andor remediate contamination result past industrial activity company current site waste disposal reprocess facility operate party cercla matter respect cercla matter company responsible state federal foreign law company typically estimate potential cost base information obtain environmental protection agency counterpart state foreign agency andor study prepare independent consultant include total estimate cost site expect costshare potentially responsible party company accrue liability probable reasonably estimable company estimate share future cost site million december represent sum good estimate good estimate reasonably estimate minimal probable range cost take account potential recovery party million include estimate cost additional probable loss associate previously disclose north brunswick township high school remediation site note select quarterly financial datum unaudite dollar million share datum quarter second quarter quarter fourth quarter year total revenue gross margin net earning net earning attributable noncontrolle interest bms earning share basica earning share diluteda cash dividend declare common share cash cash equivalent marketable securitiesb total asset longterm debtc equity dollar million share datum quarter second quarter quarter fourth quarter year total revenue gross margin net earningsloss net earningsloss attributable noncontrolle interest bms earningsloss share basica earningsloss share diluteda cash dividend declare common share cash cash equivalent marketable securitiesb total asset longterm debt equity earning share quarter add amount year period compute discrete basis marketable security include current noncurrent asset longterm debt include current portion follow specify item affect comparability result second fourth dollar million quarter quarter quarter quarter year cost product solda license asset acquisition charge iprd impairment accelerate depreciation research development provision restructure litigation settlement divestiture gain royalty license income pension charge intangible asset impairment incomeexpense increasedecrease pretax income income tax item increasedecrease net earning specify item cost product sell accelerate depreciation asset impairment shutdown cost second fourth dollar million quarter quarter quarter quarter year cost product solda marketing sell administrativeb license asset acquisition charge iprd impairment accelerate depreciation research development provision restructure litigation settlement divestiture gainslosse pension charge intangible asset impairment write option adjustment loss debt redemption incomeexpense increasedecrease pretax income income tax item increasedecrease net earning specify item cost product sell accelerate depreciation asset impairment shutdown cost specify item marketing sell administrative process standardization implementation cost report independent register public accounting firm board director shareholder bristolmyers squibb company audit accompany consolidated balance sheet bristolmyer squibb company subsidiary company december relate consolidated statement earning comprehensive income cash flow year period end december financial statement responsibility company management responsibility express opinion financial statement base audit conduct audits accordance standard public company accounting oversight board united states standard require plan perform audit obtain reasonable assurance financial statement free material misstatement audit include examine test basis evidence support amount disclosure financial statement audit include assess accounting principle significant estimate management evaluate overall financial statement presentation believe audits provide reasonable basis opinion opinion consolidate financial statement present fairly material respect financial position bristolmyer squibb company subsidiary december result operation cash flow year period end december conformity accounting principle generally accept united states america audit accordance standard public company accounting oversight board united states company internal control financial reporting december base criterion establish internal controlintegrate framework issue committee sponsor organization treadway commission report date february express unqualified opinion company internal control financial reporting deloitte touche llp parsippany new jersey february item change disagreement accountant account financial disclosure item control procedure evaluation disclosure control procedure december management carry evaluation supervision participation chief executive officer chief financial officer effectiveness design operation disclosure control procedure term define exchange act rule base evaluation management conclude december disclosure control procedure effective management report internal control financial reporting management responsible establish maintain adequate internal control financial reporting supervision participation management include chief executive officer chief financial officer management assess effectiveness internal control financial reporting december base framework internal controlintegrate framework issue committee sponsor organization treadway commission base assessment management conclude company internal control financial reporting effective december provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance united states generally accept accounting principle inherent limitation internal control financial reporting prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate deloitte touche llp independent register public accounting firm audit company financial statement include report issue report effectiveness company internal control financial reporting december include change internal control financial reporting change company internal control financial reporting quarter end december materially affect reasonable likely materially affect company internal control financial reporting item information report independent register public accounting firm board director shareholder bristolmyers squibb company audit internal control financial reporting bristolmyer squibb company subsidiary company december base criterion establish internal controlintegrate framework issue committee sponsor organization treadway commission company management responsible maintain effective internal control financial reporting assessment effectiveness internal control financial reporting include accompany management report internal control financial reporting responsibility express opinion company internal control financial reporting base audit conduct audit accordance standard public company accounting oversight board united states standard require plan perform audit obtain reasonable assurance effective internal control financial reporting maintain material respect audit include obtain understand internal control financial reporting assess risk material weakness exist test evaluate design operating effectiveness internal control base assess risk perform procedure consider necessary circumstance believe audit provide reasonable basis opinion company internal control financial reporting process design supervision company principal executive principal financial officer person perform similar function effect company board director management personnel provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle companys internal control financial reporting include policy procedure pertain maintenance record reasonable detail accurately fairly reflect transaction disposition asset company provide reasonable assurance transaction record necessary permit preparation financial statement accordance generally accept accounting principle receipt expenditure company accordance authorization management director company provide reasonable assurance prevention timely detection unauthorized acquisition use disposition company asset material effect financial statement inherent limitation internal control financial reporting include possibility collusion improper management override control material misstatement error fraud prevented detect timely basis projection evaluation effectiveness internal control financial reporting future period subject risk control inadequate change condition degree compliance policy procedure deteriorate opinion company maintain material respect effective internal control financial reporting december base criterion establish internal controlintegrate framework issue committee sponsor organization treadway commission audit accordance standard public company accounting oversight board united states consolidated financial statement year end december company report date february express unqualified opinion consolidated financial statement deloitte touche llp parsippany new jersey february iii item director executive officer registrant reference proxy statement file march respect director registrant incorporate reference hereof response information require item information require item respect executive officer registrant include reliance general instruction instruction item regulation item executive compensation reference proxy statement file march respect executive compensation incorporate reference hereof response information require item item security ownership certain beneficial owner management relate stockholder matter reference proxy statement file march respect security ownership certain beneficial owner management incorporate reference hereof response information require item item certain relationship relate transaction reference proxy statement file march respect certain relationship relate transaction incorporate reference hereof response information require item item auditor fee reference proxy statement file march respect auditor fee incorporate reference hereof response information require item item